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ABSTRACT 
Amines are a prominent functionality found throughout organic molecules, including pharmaceuticals, 
agrochemicals, organic materials, and organic dyes.1 However, incorporation of amines into organic 
frameworks in step and atom economical fashion remains a significant challenge to synthetic chemists.2–4 
In chapter 1, the importance of a class of compounds, 1,2-diamines is reviewed. Herein, many marketed 
pharmaceuticals, potential therapeutics, and natural products bearing this motif of interest are discussed. 
Additionally, 1,2-diamines have been shown as ligands for catalysis. Due to this interest in the 1,2-diamine 
functionality, some current synthetic methods to access 1,2-diamines will be shown. 
Chapter 2 discusses the hypothesis that a Lewis basic functionality could coordinate to a metal center 
and allow a hydroamination reaction to occur. Hydroamination was seen as a beneficial strategy to 
synthesize 1,2-diamines as olefins and amines are reacted in an atom-economical fashion. Initial reaction 
discovery of the rhodium-catalyzed intermolecular hydroamination of N-allylimines will be shown as well 
as reaction development. It was found that modest to high yields and high diastereoselectivities were 
obtained to synthesize 1,2-diamines with this methodology. 
 
Further, reaction development of secondary and primary N-allylamines will be discussed. These 
substrates offer attractive methods toward synthesizing 1,2-diamines by being easy to access. When 
secondary N-allylamines are employed, good yield is obtained for the desired hydroamination reaction. 
 
Excitingly, primary N-allylamines were able to be used as substrates for this transformation. This 
substrate class offered the shortest reaction times and proved to be effective for a wide range of amine 
nucleophiles. 
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CHAPTER 1 
Importance of 1,2-Diamines as Targets for Reaction Development 
 
1.1. Introduction to Our Proposed Reaction 
Amines are a prominent functionality found throughout organic molecules, including pharmaceuticals, 
agrochemicals, organic materials, and organic dyes.1 However, incorporation of amines into organic 
frameworks in step and atom economical fashion remains a significant challenge to synthetic chemists.2–4 
Transition metal-mediated hydroamination, the addition of an N–H bond across a C=C bond, is one of the 
most attractive routes for the generation of C–N bond as it couples two easily accessible functionalities and 
does not generate any stoichiometric byproducts.5,6 Although there has been significant research devoted to 
the development of an efficient and general hydroamination reaction, the current scope of these reactions 
is fairly limited. 
The first major challenge facing the development of a practical hydroamination reaction is that it can 
afford two isomeric products: the Markovnikov or the anti-Markovnikov product where the new C–N bond 
is generated at the more or less substituted carbon, respectively. The second significant challenge is that the 
reactions often generate a mixture of both the hydroamination and the oxidative amination product (Scheme 
1).7–21 A third challenge, as the amines are often much better ligands for the metal, is that the olefin 
containing substrate is required in moderate to great excess in order to favor association to the metal 
center.14–21 These transformations often require intramolecular reaction to take place as well.7–13 Finally, 
electronically activated substrates, which can generate π-allyl or π-benzyl intermediates, are often required 
to react.14–16,22–27  
 
The goal of this project was to develop a Rh-catalyzed hydroamination reaction that does not rely on 
either an intramolecular reaction or electronically activated olefins to achieve an active and selective 
catalytic system. Our approach was to employ substrates that have heteroatom groups that can bind to the 
catalyst and increase the affinity of the olefin to coordinate to the catalyst (Scheme 2). Ideally, this would 
remove the need to use conjugated or strained substrates. 28–32  
Two mechanisms are proposed throughout the hydroamination literature, an inner-sphere and outer-
sphere mechanism.3,4,19,33,34 In the inner-sphere mechanism, the amine N-H bond undergoes oxidative 
addition followed by insertion in to the olefin. After reductive elimination or beta-hydride elimination, the 
amine or enamine product, respectively, is formed. In the outer-sphere mechanism, aminometallation is the 
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key N-C bond-forming step. Upon the aminometallation, a metallacycle can be generated, directing both 
the regioselectivity of the nucleophilic attack and helping to prevent ß-hydride elimination (Scheme 2).35,36 
By using an allylimine or allylamine to coordinate to the rhodium (I) catalyst, it was anticipated that an 
outer-sphere pathway will be operable as seen in Scheme 2. 
 
Herein, the discovery of such a reaction is discoursed. First, the importance of the products that can 
be generated, 1,2-diamines, will be discussed. This is followed and brief discussion on ligand scaffolds 
featuring 1,2-diamines as well as some of the most popular synthetic routes toward 1,2-diamines. This 
will transition into a brief discussion on late transition metal catalyzed hydroamination as a potentially 
viable and attractive approach towards forming these products. The choice of rhodium as a metal catalyst, 
followed by all optimization and reaction development will be shown.  
 
1.2. 1,2-Diamines in Pharmaceuticals 
Using a hydroamination strategy employing a Lewis-basic directing group, a 1,2-relationship between 
the Lewis-basic imine or amine and the amine nucleophile will be formed after hydroamination. The 
proposed hydroamination reaction using allylimines would form aminoimines, which can be reduced to 
form protected 1,2-diamines. This functionality has found extended use in marketed pharmaceuticals and 
well as potential therapeutics that are not yet marketed. Cisplatin, a potent anti-cancer compound class, has 
been widely studied by varying the amine-based ligands of the platinum complex. The method reported 
herein can be useful towards more streamlined syntheses to these 1,2-diamine moieties, though more studies 
will be performed to improve substrate scope with respect to internal alkenes and to improve nucleophile 
scope to encompass primary amines, secondary, acyclic amines, and ammonia.  However, nitrogen-
containing heterocycles have found prevalence in the U.S. FDA approve pharmaceuticals.37 Additionally, 
84% of the top 200 pharmaceuticals by sales contain at least one nitrogen atom and 59% contain at least 
one nitrogen heterocycle, highlighting the importance of developing an efficient methods towards their 
synthesis and incorporation of nitrogen-based functionality into those molecules.37 
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1.2.1. Marketed Pharmaceuticals 
Few potentially active pharmaceuticals make the journey to clinical trials after initial development in 
the laboratory. However, the compounds that succeed in clinical trials and make it to the market largely 
contribute to the success of pharmaceutical companies. The 1,2-diamine moiety has emerged as an 
important motif in a handful marketed compounds which can be separated into two categories; compounds 
with substitution vicinal to the amine moieties and compounds bearing the ethylene diamine motif. 
Marketed compounds with substitution vicinal to one or both of the amines in these pharmaceuticals are 
underdeveloped. This could be attributed to limited accessibility of these compounds in screening by 
medicinal chemists. The methodology reported, herein, can be useful in providing access to these new 
compounds with an overall similar structure. 
There are a handful of marketed compounds that could potentially be accessed in the future using the 
reported rhodium-catalyzed hydroamination (Figure 1). Although the current methodology may not access 
all of the molecules shown in Figure 1, there is certainly a challenge to access the molecules efficiently. 
oseltamivir phosphate (1) is a marketed anti-influenza compound commonly administered orally. This 
compound is believed to inhibit neuramidase, an enzyme present in infected cells that allows for the release 
of the virus throughout the body.38 Although the molecule bears only three stereocenters on a cyclohexene 
moiety, methods for accessing the corresponding 1,2-diamine are not well developed and often require 
multiple steps to access.39 The industrial synthesis of Tamiflu™ currently involves a 12 step synthesis with 
an overall yield of 18% (Scheme 3) from (-)-shikimic acid (13).40–42 Because of the high demand of this 
pharmaceutical and the availability of (-)-shikimic acid to be isolated on large scale from Illicium verum 
(Chinese star anise), alternative approaches have been pursued from readily accessible starting materials.43–
49 The synthesis reported by Trost (Scheme 4) is the shortest synthesis to date, consisting of 8 steps and 
30% overall yield from a readily accessible lactone (14).50  
In recent years, Oseltamivir derivatives have been extensively studied yielding two similar 
pharmaceuticals that are currently marketed. zanamivir (2), the first neuraminidase inhibitor commercially 
developed, is currently marketed by GlaxoSmithKline.38,39,51 Laninamivir (3)38 has been marketed in Japan 
and is currently in Phase III clinical trials in the U.S.  In light of these 1,2-diamine based anti-viral agents 
being relatively well received in the market, there have been extensive efforts to understand the binding52–
55 of the compounds to neuraminidase, and many other similar compounds have been shown to be effective 
toward inhibiting this enzyme.41,51–57 
Promethazine (4), propiomazine, (5), and profenamine (6) have been available on the market for an 
extended period of time. Promethazine has been investigated more in-depth compared to propiomazine. 
Promethazine has been marketed for over 60 years and is often used as a sedative and anti-histamine.37,58–
60 Propiomazine has been used as an anti-histamine and is known to have a binding affinity for α2-
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adrenoreceptors.37,61 However, there are many side-effects associated with these pharmaceuticals including 
dizziness, sedation, and has anticholinergic properties resulting in recreational use when contained in cough 
syrup.62–66 Profenamine also has similar properties as the two former.67–70  
Another 1,2-diamine-containing pharmaceutical is nemonapride (7). Nemonapride acts as an 
antipsychotic for treatment of schizophrenia. The mode of action for nemonapride is as a D2 and D3 receptor 
antagonist and 5-HT1A receptor agonist.71–76 One compound used to treat cystic fibrosis, aztreonam (8), 
could be potentially be synthesized using this methodology.77–82 Lisuride (9), an antiparkinson agent, also 
could be synthesized using this methodology.83,84 Besifloxacin (10), is commonly used as an antibacterial 
in eyedrops.85,86 Propiram (11) is a µ-opioid receptor agonist that was developed by Bayer.60,87 Recently 
taken off of the market, bepridil (12), is still being studied as it was once used to treat chest pain.88–92 Rapid 
derivatization could lead to a more effective drug candidate with fewer side effects. 
Although these 1,2-diamines are limited with respect to the current substrate scope, the 1,2-diamine 
functionality is very prevalent in pharmaceuticals. However, vicinal substitution is not present in most of 
the currently marketed pharmaceuticals. Some of this may be attributed to synthetic methods to access these 
compounds. In a recent review,93 the methylation effect in medicinal chemistry was discussed. It is observed 
in many pharmaceuticals and natural products that addition of a methyl group in various locations of a 
compound can drastically improve favorable interactions with target sites. However, due to synthetic 
limitations, methyl group substitution adjacent to amines present in 1,2-diamine motifs have not been 
studied. The reactivity of methylated substrates could be beneficial to drug development. Using the 
hydroamination methodology described herein, access to methylated substrates on 1,2-diamines can be 
synthesized.  
Rhodium-catalyzed hydroamination could be a productive method towards further investigating 
marketed drug compounds. Although these targets have been approved in various markets, all contain 
varying levels of side-effects. It would be beneficial towards drug development to have access to targets 
containing a methyl group where traditional synthetic methods are challenging to employ. 
A 1,2-diamine that could be further investigated is metoclopramide (15), a dopamine receptor 
antagonist known to reduce nausea and vomiting.94–99 Three similar compounds that could be investigated 
include Procainamide (16),99–103 declopramide (17),99,104–106 and a commercially available antidepressant, 
moclobemide (18). 107–109 All of these compound could be derivatized to include a methyl group at either 
vicinal position.  
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Perhaps the most important discovery with respect to antihistamines was made by Dr. Daniel Bovet 
who discovered mepyramine (19)59,110–117 and was awarded the 1957 Nobel Prize in physiology or 
medicine.118 This shows the importance of this compound though further derivatives have not been 
explored. This hydroamination methodology would allow for simple derivatives to be investigated. 
Tripelennamine (20) also has similar activity as an antihistamine and is currently marketed by 
Novartis.110,111  
Another drug is minaprine (21), an anti-depressant bearing the 1,2-diamino moiety, but it was removed 
from the market, because the drug was believed to cause convulsions.119–123 It would be interesting to 
observe reactivity and side effect differences by adding a methyl group next to one of the amine 
functionalities to observe a methylation effect that could influence solubility, uptake, or binding.93 
Guanethidine (22) is an antihypertensive drug often used.124–126 Zetidoline (23) is a dopamine D2 receptor 
antagonist.98,127–130 All of these pharmaceuticals would be interesting targets to investigate via the 
methylation effect and the hydroamination methodology would allow for easy access to these molecules.  
The final compounds that could be further explored include sertindole (24), sunitinib (25), mitoxantrone 
(26), pixantrone (27), diltiazem (28), flurazepam (29), and ethambutol (30). Sertindole is an antipsychotic 
that could be investigated.131–135 Sunitinib, an anticancer agent, could be readily derivatized to explore the 
methylation effect on its anticancer activity and side-effects.102,136–140 Mitoxantrone141–146 and, more 
recently, Pixantrone142,147–150 have been used to treat certain types of cancer. Diltiazem is a calcium channel 
blocker which is used to treat hypertension.151–154 Flurazapam, a sedative, could also be studied in this 
manner.155–161 Interestingly, ethambutol,162–165 an antimycobacterial used to treat tuberculosis, was 
investigated in this way by adding various substituents to the drug.166,167  These were evaluated, not by 
adding substituents internally relative to the 1,2-diamine moiety, but were substituted away from the 1,2-
diamine moiety. The rhodium-catalyzed hydroamination would allow a complementary method towards 
exploring effects of substitution. 
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1.2.2. Potential Therapeutics 
In addition to marketed pharmaceuticals containing 1,2-diamine functionalities, there are many 
biologically active compounds that contain 1,2-diamine subunits with vicinal substitution. There are two 
classes of compounds to be discussed; compounds which could be synthesized using developed rhodium-
catalyzed hydroamination of allylamines and nucleophiles that are not yet developed.  
The first class of compounds to be discussed are recent developments with respect to the CBP and 
p300 bromodomain inhibitors. These bromodomains are involved in post-translational modification and 
some disorders are related to overactive p53 transcription.168 Excitingly, highly active inhibitors of these 
domains were recently developed (Figure 4). The stereochemistry and aromatic substitution was shown to 
play a vital role and compound 34 emerged as the most potent inhibitor of these domains. Excitingly, the 
hydroamination methodology herein should allow for rapid derivatization of this compound to explore 
other nitrogen-containing heterocycles as no additional heterocycles, apart from morpholine, were shown. 
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The next class of compounds that could be accessed via hydroamination methodology is the 
development of 2-aminoanilide histone deacetylase inhibitors. These compounds have been recently 
explored with respect to anticancer activity, because histone deacetylases are important in post-
translational modification.169 Two representative compounds shown to have inhibitory effects are 
compound 39 and compound 40 (Figure 5). These were shown to have promising anticancer activity.169 
As these compounds become better understood, hydroamination to form the 1,2-diamine subunit could 
prove useful in rapid derivatization of the amine functionality. 
 
An interesting class of compounds include those derived from nocathiacins. These antibiotics are 
isolated from the bacterium Norcadia sp. and fungus Amicolaptosis sp.170 Nocathiacins have been shown 
to have good efficacy against Staphylococcus aureus. However, poor water solubility has limited their use 
in the clinic.170 This lead to the investigation of developing more water-soluble derived compounds. In an 
exciting result, several potent analogs were synthesized and one such compound was compound 41 which 
showed very good activity against three bacterium.170 It was shown that by adding basic functionality to 
the nocathiacin, water solubility was increased (Figure 6). 
Another class of compounds recently explored include renin inhibitors. The renin-angiotensin system 
is one of the regulators of blood pressure.171 Because of his, inhibitors have been developed which can 
control the release of renin in the system, thereby treating hypertension and heart failure (Figure 7). 
Compound 42 was shown to be an effective inhibitor by adding the 1,2-diamine moiety to the compound.172 
More recently, compound 43 was found to have similar effects with high binding affinity and higher water 
solubility. 
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 An important class of compounds include opioid receptor agonists. In one example, the κ opioid 
receptor was investigated. This receptor is known to lead to sedation when activated.173 Three highly active 
compounds were investigated, among others (Figure 8). Compounds 44-46 showed varying binding and 
potency with compound 44 being the most effective and compound 45 as the least effective. 
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 Another class of compounds that are currently being investigated are poly(ADP-ribose) polymerase 
inhibitors that are useful for cancer therapy and diseases related to inflammation.174 Interestingly, amines 
were studied as suitable compounds as represented by compounds 47 and 48 (Figure 9) and 47 is being 
further investigated. Also, amnesia-reversal compounds have been studied to act against memory loss 
(Figure 10).175 Both compounds 49 and 50 showed similar effectiveness at restoring memory. The use of 
hydroamination methodology in both cases can lead to rapid derivatization of these compounds using 
different nucleophiles. 
 
 
The final three compounds to be discussed are similar in structure but have different medicinal effects. 
Compound 51 has been shown to have anti-HIV effects by acting as an HIV-integrase inhibitor (Figure 
11).176 Compound 52 has been shown to act as a calcium channel blocker with diltiazem-like (compound 
28) activity for treatment of cardiovascular diseases and was reported as a useful structure due to the limited 
accessibility of diltiazem-like compounds.152 Finally, a potent GlyT1 inhibitor, compound 53, has been 
shown to be effective at treating schizophrenia by increasing brain glycine levels.177,178 
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It is evident that the currently developed hydroamination methodology could be useful in generating 
screening libraries and as a regio- and chemoselective synthesis towards a variety of biologically active 
molecules. However, this hydroamination methodology will be further developed to include internal 
alkenes as well as amides, acyclic, secondary amines, and primary amines to further provide utility towards 
the synthesis of 1,2-diamines. 
The first class of compounds that could be investigated are β-secretase inhibitors (Figure 14). This class 
of compounds is important for the treatment of Alzheimer’s disease. BACE-1 is known to catalyze the 
formation of β-amyloid, a major component of neuritic plaques.179 Excitingly, 54 and 61 were shown to be 
the most effective inhibitors of β-secretase with all compounds displaying various degrees of potency.179–
181 Although hydroamination of internal alkenes remains a significant challenge, in the future 
hydroamination could allow to rapid access to these enantiopure derivatives. 
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Another important class of compounds are anti-malarial agents. Recently reported are a class of 
macrolactams bearing a 1,2-diamine moiety (Figure 15).182–184 Compounds 62-67 were shown to have 
effective potency against a few different strains of malaria, with 62 being the most effective. However, 
more screening is needed to ensure greater potency and solubility. Hydroamination off allylamine 
derivatives could potentially enhance the ability to synthesize derivatives of these compounds. 
Similarly, a class of dispiroperoxides have been reported as potential anti-malarial agents (Figure 16).185 
Since the discovery of artemisinin as a potent antimalarial natural product, synthetic derivatives have been 
investigated. 68 was shown to have activity levels against malaria strains and further generations are being 
developed to increase potency.185 
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An important class of compounds, opioid receptor agonists have also been investigated (Figure 
17).1,173,186–191 Compound 72, U50,488, represents an early example of a κ-opioid receptor agonist. These 
compounds are important as they help decrease pain, inflammation, and can  induce sedation.186 Since the 
discovery of U50,488, similar synthetically derived compounds have been investigated (Figure 18). 1,173,186–
16 
 
191 The (+)-enantiomer of U50,488 (73) is known to have decreased activity compared to (-)-U50,488 
(72).186 Cyclic derivatives (74-79)186,189,190 and linear derivatives (80-83)173 have been investigated. 
Interestingly, very similar compounds to 72 were shown to be effective as agonists for different opioid 
receptors; 74 (σ) and 75 (µ).186 These 1,2-diamine motifs are shown to be important with respect to opioid 
receptor activity, and the methodology reported herein could potentially be used in the future to aid in 
developing screening libraries for derivatives of 72. 
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Another type of compound used for treatment of malaria are mefloquine derivatives (Figure 18).192 A 
screening library was synthesized and were all shown to have differing potency against malaria. One 
downside to this diverse library is the exploration of diamine substrate with the methyl group adjacent to 
the heterocyclic amine. Our methodology would provide a complementary approach towards accessing 
derivatives of 83-91. 
 
Another important class of potential pharmaceuticals are poly(ADP-ribose) polymerase (PARP) 
inhibitors. PARPs are known to be activated during inflammation events or cancer therapy and enables 
cancer cells to repair DNA which often leads to mutations contributing to drug resistance.174  A library of 
compounds were screened and shown to have varying activities. A representative group of products are 
shown in Figure 19. Interestingly, 92 showed very promising activity and is being further investigated. 
 
Chronic myeloid leukemia has been studied recently, and it has been shown that a kinase inhibitor (96) 
has increased potency relative to currently marketed compounds.193 This could lead to decreased mutations 
18 
 
that allow for drug resistance. Hydroamination from a common precursor could lead to the development of 
a screening library to observe enhanced potency with respect to the 1,2-diamine motif (Figure 20).193,194  
 
A well-studied area of research are anti-cancer drugs that can interact with DNA. Recently, bis-
intercolators such as 96 (Figure 21) have been studied with increase affinity to DNA and a longer time for 
cells to develop drug resistance.147 Although this compound is unable to be synthesized with current 
hydroamination methodology, once imides can be used as nucleophiles, this would be able to lead to a 
useful synthesis of 96. 
 
There are a variety of 1,2-diamine containing compounds that have been explored for biological 
activity, and a multitude of these compounds could arise from hydroamination of internal alkenes using 
primary amine, amide, or acyclic secondary amine nucleophiles (Figure 22). Benzodiazepines are known 
to have a wide variety of biological activity, but 97 and 98 have shown good anticancer activity.195–197 
Mitotic kinesin inhibitor, 99,198 renin inhibitor, 100,199,200 protein kinase inhibitor, 101,201,202 GlyT1 
inhibitor, 102,203 κ-opioid antagonist, 103,188,204 and  GlyT1 inhibitor GSK931115, 104,205–208 could all be 
potentially synthesized through hydroamination using internal alkenes with various nucleophiles. 
There are also a variety of 1,2-diamine containing compounds that have been explored for biological 
activity that could arise from hydroamination of terminal alkenes using primary amine, amide, or acyclic 
secondary amine nucleophiles (Figure 23). Opioid agonists 105 and 106 have been shown to have good 
activity for the µ-opioid receptor and are dependent on the methyl substituents shown (Figure 23).209 Also, 
RNA polymerase inhibitors 107 and 108 were shown to have anticancer activity.210 Additionally, an MDM2 
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inhibitor, 109, has been shown to have anti-tumor activity.211 All of these could potentially be synthesized 
using the developed hydroamination methodology.  
The final class of compounds to discuss are imaging agents used in the medical field. Cross-linking 
compounds continue to be studied as compounds that bind to DNA in cancer cells. This can enable easier 
imaging when coordinated to a radioactive label. Two examples can be seen in Figure 24. Compounds 110 
and 111 were shown to be used in low amounts and were reliable for molecular imaging.212,213 
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1.2.3. Natural Products 
Natural products are an important class of compounds for the discovery and application of therapeutic 
agents. The 1,2-diamine motif can be found in a wide variety of natural product classes, and this motif has 
been found to have various roles with respect to biological activity. Although the current hydroamination 
methodology is unable to access these compounds reported herein, future work can be performed to address 
the nucleophile and alkene scope of the developed rhodium-catalyzed hydroamination. Also, this 
methodology could allow for the synthesis of unnatural natural products by creating building block that 
allow for the investigation of the methylation effect in medicinal chemistry.93 
The first class of natural products to discuss are macrocyclic polypeptide natural products (Figure 25). 
These compounds (112-119) all contain a 1,2-diamine moiety. This would allow for the use of this 
methodology to incorporate this methylated 1,2-diamine building block into the synthesis of these natural 
products. Viomycin, 112, is an anti-tuberculosis natural product that is isolated from many different 
organisms.214–217 A similar natural product, capreomycin (113), has been shown to have similar anti-
Mycobacterium tuberculosis activity.214,218–225 GE23077 compounds 114 and 115 have shown to exhibit 
very good RNA polymerase inhibition in bacterium.222,226 Cyclocinamide, 116, has been isolated from 
marine sponges and has exhibited broad biological activity.222,227,228 The final two cyclic polypeptides 
containing the 1,2-diamine moiety are nepadutant (118) and laspartomycin C (119). Nepadutant is a 
tachykinin NK-2 receptor antagonist which is being studied as a potential treatment for asthma, bronchial 
hyperreactivity, and irritable bowel syndrome.222,229,230 Laspartomycin C is synthesized by bacterium and 
has shown to exhibit broad antibacterial activity.222,231–233 It can be seen that these natural products are all 
important synthetic targets, but due to their complexity, derivatives have rarely been studied. 
Hydroamination of alkenes could lead to a useful method to explore methylation of these compounds 
through the synthesis of simpler 1,2-diamine building blocks. 
The next set of compound bearing a 1,2-diamine functional group that could be further derivatized can 
be seen in Figure 26. KMI-684 is a β-secretase inhibitors which is important for the treatment of 
Alzheimer’s disease.222,234,235 The disulfide bridged NMe-Azathiocoraline, 121, is a DNA-intercalating 
compound with anti-cancer activity.222,236–239 Both of these compounds could show significant increase or 
decrease in activity based on simple methyl-substitution.93 Additionally, peplomycin, 122, has shown very 
good anti-tumor activity by cleaving DNA,222,240–242 and SCH37137, 123, has shown antibacterial activity 
by suppressing microbe growth.222,243 Finally, dapdiamide A, 124,222,244,245 and zwittermycin A, 125,222,246–
248 have shown broad anti-bacterial activity. 
22 
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Perhaps the most important class of 1,2-diamine natural products with respect to hydroamination 
methodology are those bearing a methyl substituent at the same position as one amine functionality (Figure 
27).93  Mureidomycin A, 126, has been shown to be an effective peptidoglycan biosynthesis inhibitor; acting 
as a gram-positive anti-bacterial.222,249,250 Napsamycin A, 127, has also been shown to have very good anti-
bacterial activity.222,230 Cirratiomycin B, 128, and lavendomycin, 129, also have very good antibiotic 
activity.222,251 Lastly, the antibiotic, pacidamycin 3 (130),252–256 and the anti-HIV compound, papuamide B 
(131),222,257–261 could potentially be synthesized using hydroamination methodology. 
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This hydroamination methodology could also be useful at derivatizing internal alkenes in order to build 
complexity (Figure 28). Cicadapeptins 132 and 134 were isolated from the Australian cicada and have 
shown promising antibiotic activity.262 Epiquinamide, 133, and laburnamine, 134,263 have been shown to 
possess agonistic activity with respect to nicotinic acetylcholine receptors which are known to be involved 
in primary functions of the central nervous system. Absouline, 136, 264–268 and slaframine, 137,190,269–273 
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have been shown to possess moderate antiviral activity while guadinomine, 138, possesses gram-negative 
antibacterial activity.274 
 
Finally, this hydroamination methodology could potentially be used as a method to synthesize complex, 
small molecule, natural products. Antibiotic 139, streptothricin F,222,275 protein kinase inhibitor 140, 
balanol,190,276–282 anti-cancer compound 141, agelastatin A,283–288 and antiproliferative agent 142, 
jogyamycin,289 all possess the 1,2-diamine functionality. However, current hydroamination methodology 
would not be able to synthesize these compounds. 
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1.3.  1,2-Diamines as Ligand Scaffolds 
1,2-Diamines are employed as ligands in a variety of 
reactions. A beautiful review was published by Buchwald 
on diamine ligands in copper-catalyzed reactions.290 Many 
of the reactions reported have shown usefulness in the 
pharmaceutical industry for cross-coupling and other 
reactions. Additionally, Noyori has shown effective 
ruthenium catalysts for hydrogenation.291,292 One such 
catalyst is shown in Figure 30. 1,2-diamines have also been employed in a vast array of iridium-catalyzed 
hydrogenation and transfer hydrogenation.293 
Perhaps one of the most well-known diamine-derived catalysts is the Jacobsen epoxidation catalyst 
(Figure 31). This diamine has been utilized in a wide-variety of ways, but few other derivatives of the 
chiral diamine portion are known.294–297 Additionally, Grubbs employs a chiral NHC derived from a 
diamine for metathesis reactions (Figure 32).298–300 
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Lastly, the Song group has developed a chiral ligand which is efficient in the catalytic 
enantioselective cross-aldol reaction between linear aliphatic ketones and fluorinated ketones (Scheme 
5).301 The authors noted that by fine-tuning the diamine catalyst, a wide range of enantioselectivities were 
obtained.  
 
There are many other ligands for catalysis that are not discussed here that contain 1,2-diamine 
moieties. The hydroamination methodology reported herein would allow the derivatization of some of 
these ligand scaffolds that could impact both reactivity and enantioselectivity. 
   
1.4. Synthesis of 1,2-Diamines  
Typically, 1,2-diamines are synthesized in a multi-step fashion. Therefore, it would be desirable to 
synthesize diamines through reaction with 1,2-dihalides. However, when these reactions are conducted, 
elimination byproducts are formed preferentially.190 Hydroamination would be a step and atom-economical 
approach toward this problem. Traditionally, 1,2-diamines are synthesized through aziridination followed 
by nucleophilic ring-opening, the Nitro-Mannich reaction, 1,2-diamination of olefins, and Cope-type 
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hydroamination. These methods will be discussed among other unique approaches, and the state-of-the-art 
methods will be discussed in detail.  
 
1.4.1. Aziridine Ring-Opening  
Nucleophilic addition of amines to aziridine containing molecules has been a known transformation for 
over 30 years.302 However, it was noted that the corresponding aziridine could undergo ring-opening in an 
SN2 fashion or undergo a single-electron transfer mechanism, forming a radical, and producing the opposite 
regioselectivity.302 Due to unpredictable regioselectivity, aziridine ring-opening has been well-studied using 
a variety of nucleophiles. When amine nucleophiles are used, the final product contains a 1,2-diamine. In 
addition to regioselectivity problems, unprotected aziridines can act as nucleophiles themselves which 
causes chemists to protect the aziridine before nucleophilic ring-opening.190 It would be desirable to instead 
form a 1,2-diamine directly from an olefin. A large portion of work has been dedicated to the stereoselective 
synthesis of aziridines,303 but the regioselective opening of aziridines will primarily be discussed in this 
report. 
There are two notable examples that exhibit exquisite regioselectivity. First, it was shown that 1,2-
diamines could be formed in high selectivities from alkyl aziridines (Scheme 6).304 Catalyzed by 
tetrabutylammonium fluoride, this reaction proceeds in high yield with the nucleophile adding to the more 
substituted position of the aziridine ring. This regioselectivity differs from what would be expected from 
an SN2-type ring opening. 
 
The second example could be considered the state-of-the-art method for synthesizing chiral 1,2-
diamines from trisubstituted aziridines (Scheme 7).305 This method allows for the nucleophile to add to the 
more sterically hindered position and the opposite regioisomer is not observed. The yields of this reaction 
were excellent in most cases and secondary and primary amines are tolerated as nucleophiles. 
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1.4.2. Mannich and Nitro-Mannich Reaction 
Another powerful approach towards the generation of 1,2-diamines is by the use of the nitro-
Mannich (aza-Henry) reaction. This process involves the addition of a nitronate to an imine which 
generates a new carbon-carbon bond. This process has been very well-studied and has found use in 
generating differentially protected nitrogen functionalities in different oxidation states.306,307 This allows 
for selective transformation of these functional groups. Although widely studied showing a diverse series 
of transformations, there are two notable examples that will be discussed in this report. 
The first example is the development of a syn-selective nitro-Mannich reaction (Scheme 8).73,308 
Typically, the nitro-Mannich reaction leads to the anti diastereomer.306 Interestingly, when promoted by a 
Cu/Sm/dinucleating Schiff base system, the syn diastereomer can be achieved in good to very good 
enantiomeric ratios. This diastereoselectivity is explained by the coordination of the catalyst to both the 
Boc-protected amine as well as the nitro-group in the transition state. To further show the reaction’s 
effectiveness, the authors used this methodology to synthesize the antipsychotic agent, nemonapride (7).  
 
The second example is a Mannich reaction that is a direct three-component reaction that leads to α,β-
diamino acid derivatives (Scheme 9).309 It was shown that a variety of aromatic aldehydes, secondary 
amines, and iminoesters could be combined in one-pot with a Lewis acid to afford 1,2-aminoimines. 
These were reduced in order to form the diamine acid derivatives. The yields were excellent in most 
cases, though aliphatic aldehydes showed diminished yields and selectivities. Work in this area is ongoing 
to address this limitation. 
30 
 
 
 
1.4.3. Diamination of Olefins 
An attractive approach towards the synthesis of 1,2-diamines is through direct diamination of olefins. 
This has been studied extensively, including the use of transition metal catalysis.310 The main limitations 
of this methodology include the use of unactivated terminal olefins and diamination of unactivated 
internal alkenes. The two methods discussed herein are the most recent and effective examples of 
diamination. 
The first to be discussed was able to achieve diamination of unactivated terminal alkenes using 
palladium catalysis (Scheme 10).311 Using allylic ethers, it was shown that differentially protected 1,2-
diamines could be formed. However, the olefin in this case is required in excess to give moderate yields 
of the product. 
 
The next example illustrates the current state-of-the-art with respect to diamination reactions. In this 
rhodium-mediated reaction, an aziridine is formed and is subsequently converted into the corresponding 
diamine in situ.312 Diamination of styrene derivatives proceeded in very good yields (Scheme 11). 
However, when aliphatic alkenes were used as the substrate, yield were halved (Scheme 12). Work in this 
area to further expand the alkene scope as well as making this an enantioselective process are ongoing.  
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1.4.4. Cope-Type Hydroamination of Olefins 
The recently developed Cope-type hydroamination of olefins provides a unique complementary 
approach toward synthesizing 1,2-diamines. This methodology employs a chiral aldehyde to induce a 
temporary intramolecular reaction which affords the desired products in very good yields and 
enantiomeric ratios (Scheme 13).28,313 This methodology allows access to methyl-substituted 1,2-
diamines. However, the reaction appears to be strongly substrate dependent and aldehyde dependent. The 
rhodium-catalyzed hydroamination reported herein provides a complementary approach towards this 
methodology by allowing cyclic, secondary amines to be used as nucleophiles and is not as substrate 
dependent. 
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CHAPTER 2*  
Rhodium-Catalyzed Chemo- and Stereoselective Hydroamination 
2.1. Introduction 
As it has been demonstrated, 1,2-diamines and nitrogen-containing compounds in general are very 
important molecules for a variety of reasons. The direct addition of a nitrogen and hydrogen across an 
olefin, the hydroamination reaction, would be a desirable was to make these important functionalities. 
Amines and olefins represent readily accessible starting materials that could be coupled in 100% atom 
economy. Typically, hydroamination is hindered by high activation barriers due to high electron density of 
the nucleophile and electrophile components. Because of this, metal-catalyzed approaches toward 
hydroamination have become popular. Although significant and impressive work has been conducted with 
a variety of early and late transition metals, rhodium and iridium have shown good reactivity as well as 
functional group tolerance. Functional group tolerance, was an important consideration when choosing a 
metal catalyst to perform the Lewis-base directed hydroamination reaction. Rhodium and iridium have been 
extensively studied in terms of hydroamination and have been shown to perform intermolecular 
hydroamination on a variety of functionalized substrates at relatively low catalyst loadings.3,33,314,315 
Therefore, our initial investigations began utilizing rhodium and iridium catalysts for this reaction.  
 
2.1.1. Iridium Catalyzed Intermolecular Hydroamination 
Coulson demonstrated the first example of homogeneous transition metal-catalyzed hydroamination in 
1971 with RhCl3•(H2O)3 and IrCl3•(H2O)3,; enabling the hydroamination of ethylene with piperidine.316 
Later, Milstein demonstrated an Ir(I)  hydroamination of norbornene with aniline.317 This reaction has been 
made asymmetric with a variety of strained, bicyclic olefins.27 Iridium-catalyzed intermolecular 
hydroamination was given a significant advance in 2012 when Hartwig was able to demonstrate 
Markovnikov hydroamination of unactivated and unstrained 1-octene with benzamide nucleophiles 
(Scheme 14).318 Unfortunately, a 1.4:1 (hydroamination: oxidative amination) ratio was obtained. 
Importantly, the byproduct from 
oxidative amination was able to be 
hydrogenated in situ either by H2 
balloon or transfer hydrogenation 
with 2-propanol.  
 
 
 
* This section includes previously published material319 
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It is suggested that iridium catalysts, in general, first undergo oxidative addition into the N–H bond of the 
amine nucleophile. Next, insertion of the olefin takes place followed by either reductive elimination or -
hydride elimination to afford the hydroamination or oxidative amination product, respectively. 
 
2.1.2. Rhodium Catalyzed Intermolecular Hydroamination 
As previously mentioned, Coulson demonstrated the first example of homogeneous transition metal-
catalyzed hydroamination in 1971 with RhCl3•(H2O)3 and IrCl3•(H2O)3.316 In a significant advance, Beller 
was able to demonstrate that [Rh(COD)]BF4 catalyzes the intermolecular hydroamination of styrene with 
cyclic secondary amine nucleophiles.14 Perhaps this reaction could be describe more accurately as an 
oxidative amination reaction as enamine products were preferentially formed over hydroamination products 
(Scheme 15). However, when utilizing 
DPEphos as a ligand for this reaction rather 
than PPh3, Hartwig was able to significantly 
improve the chemoselectivity in favor of 
the hydroamination product; though 
enamine byproducts were still 
significant.320 
In contrast to the typical iridium hydroamination catalytic cycle, rhodium generally coordinates the 
desired alkene followed by inner- or outer-sphere nucleophilic attack of the amine nucleophile.3 Lastly, 
proton transfer to the rhodium catalyst and reductive elimination or direct protolytic cleavage of the Rh–C 
bond occurs to form the hydroamination product. Similar to iridium, and other transition metals, -hydride 
elimination is a competing pathway. 
 
2.2. Rhodium-Catalyzed Chemo- and Diastereoselective Hydroamination 
Many of the challenges in developing an intermolecular hydroamination have been discussed. Amines 
are typically better ligands for a metal catalyst than the desired olefinic substrate. To outcompete this 
binding, excess olefin is employed. Secondly, -hydride elimination is unable to be avoided in almost all 
cases, leading to oxidative amination byproducts. Lastly, electronically activated substrates are typically 
required and are limited to a single class of amine nucleophiles.  
In order to combat these challenges, it was envisioned that incorporating a Lewis-basic directing group 
would alleviate these challenges (Scheme 16). First, the need for moderate to high excess of olefin to 
outcompete the amine nucleophile can be mitigated through coordination of the Lewis-basic group, 
bringing the tethered olefin in closer proximity to the metal center. This would increase the relative 
concentration of olefin to the metal catalyst allowing reactivity to occur. Following formation of a 5-
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membered metallocycle post-aminometallation, proton-transfer/reductive elimination or direct protolytic 
cleavage of the newly formed Rh–C bond can occur to form the desired product. It is expected the formation 
of the metallocycle would disfavor oxidative amination byproducts arising from -hydride elimination due 
to the lack of syn-periplanar hydrogens to eliminate.  
 
With these potential challenges in hand, imines were chosen as the first directing group to explore. It 
was hypothesized that primary and secondary allylamine directing groups would bind strong to the rhodium 
catalyst, perhaps inhibiting reactivity. Imines are themselves well-known ligands for transition metals, so 
allylimines were first investigated 
 
2.2.1. N-Allylimine Reaction Discovery and Optimization 
The initial investigation began by using N-allylbenzophenone imine (143) with 0.5 equivalents of 
morpholine (144a) as the nucleophile. It was hypothesized that the olefin may need to be in excess still 
based on literature precedence for rhodium and iridium catalyzed hydroamination reactions. When the 
reaction was conducted, and analyzed by GC-MS, a peak containing a molecular ion and base peak, 308 
m/z and 114 m/z, respectively, was observed. This is consistent with hydroamination of N-
allylbenzophenone imine with morpholine. In this case, no enamine product (146a) was observed (Scheme 
17). The main byproducts were (E)-4-(prop-1-en-1-yl)morpholine (146e), benzophenone imine (146d), N-
benzhydryl-1,1-diphenylmethanimine (146f), and isomerization of the starting material to the cis and trans 
isomers of 1,1-diphenyl-N-(prop-1-en-1-yl)methanimine (146b and 146c) (Scheme 17). In order to confirm 
the product, scale-up of the reaction was conducted (Scheme 18). After purification via silica gel 
chromatography, aminoimine 3a was isolated in a 44% yield and was confirmed by 1H-NMR.  
As expected, the aminoimine product appeared to slowly decompose when exposed to the silica gel 
during column chromatography. Because of this decomposition of the imine, future isolations were 
conducted by first reducing the imine in situ with NaBH4 to form the corresponding 1,2-diamine. It was 
hypothesized that aldimines would be more reactive than their ketimine counterparts due to potential steric 
interactions with the rhodium (I) metal center. N-allyl-1-(4-methoxyphenyl)-methanimine (147) was 
chosen as the substrate of choice. After reduction of the aminoimine product (148), the diamine would 
contain the p-methoxybenzyl protecting group.  
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The first parameter of our reaction that we chose to investigate was the role of the phosphine ligand. 
By analyzing the GC-MS traces, initial screens showed a significant increase in yield for the reaction when 
using DPEphos as the phosphine ligand. We hypothesized that parameters such as solvent, silver salt, 
nucleophile equivalents, temperature, and time could all depend on the phosphine ligand chosen, I elected 
to further optimize the reaction using DPEphos while Seth Ensign investigated other phosphine ligands, 
namely dppb and dppf, in more detail.  
The next parameter investigated was the effect of silver salts and solvent used in the reactions. A 
representation of these screening reactions can be found in Table 1. All iterations of these were conducted 
and we found that the non-coordinating counter ions were more effective at promoting the desired 
hydroamination reaction. These silver salts were higher yielding across all solvents, so we chose to continue 
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with the best silver salts (AgBF4, AgSO3CF3, and AgPF6) and solvents (1,4-dioxane, acetonitrile, and 
benzene) as we investigated the equivalents of morpholine used in the hydroamination reaction. 
 
The third parameter that was investigated was the equivalents of morpholine used in the reaction. 
Interestingly, when excess morpholine was added to the reaction, the yield was increased (Table 2). The 
majority of hydroamination reactions require an excess of olefin, as it is less favorable for the olefin to bind 
to the metal than the amine; the proximal imine makes the olefin-imine substrate a significantly better ligand 
and therefore it does not need to be used in excess. To the best of our knowledge, this is the first example 
of a metal-catalyzed hydroamination reaction where the olefin can be used as the limiting reagent. 
Next, catalyst loading was optimized for the reaction. For all of the previous screening reactions, 0.36 
mol % was the catalyst loading that chosen of the rhodium (I) dimer. We chose to investigate lowering the 
catalyst loading to 0.1 mol % while also increasing the catalyst loading to 0.5 mol % and 1.0 mol % using 
three of the best silver salts from previous optimization (Table 3). Interestingly, by increasing the catalyst 
loading from 0.25 mol % to 0.50 mol %, yield was increased drastically from 63% to 93%, respectively. 
Because AgBF4 provided the best yield with fewer equivalents of morpholine at 0.5 mol % catalyst loading, 
we chose these components as optimal for the hydroamination reaction. 
The final parameters that we investigated were time and temperature. Seth Ensign performed the time 
studies and found that 24 hours was the completion time for the reaction. We then investigated the 
temperature of the reaction at different equivalents of morpholine (Table 4). We elected to move forward 
with a temperature of 60 °C and using 3-5 equivalents of morpholine, as it was found to be substrate 
dependent.  
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2.2.2. N-Allylimine Substrate Scope  
With the optimized reaction conditions in hand, the scope of the hydroamination reaction was 
investigated. First, scale-up of the hydroamination of imine 147 with morpholine, affords 148 in 92% in 
situ yield. Unsurprisingly, compound 148 is not stable to column chromatography; the imine is rapidly 
hydrolyzed to 4-methoxybenzaldehyde on silica gel. Therefore, reduction of the imine was conducted with 
NaBH4  or LiAlH4, in the case of aldimine or ketimine reduction, respectively. Upon purification by column 
chromatography, 149a was isolated in 82% yield. 
This was a collaborative effort between Seth C. Ensign, Dr. Anil Gupta, and myself. The first that we 
investigated was the imine substrate scope (Table 5). Seth Ensign found that cyclic, secondary amine 
nucleophiles performed well under reaction conditions. However the highest yields were obtained by 
determining the optimal equivalents of nucleophile for each hydroamination reaction. In the case of 
morpholine, 144a, 3 equivalents were required for the maximum yield; while only 1.5 equivalents of 
pyrollidine (144e) was required to afford 149e in 76% isolated yield. Additionally, dimethylamine was able 
to be employed as the nucleophile is this reaction. However, larger acyclic secondary amine nucleophiles 
such as N-methylbutylamine and primary amines such as cyclohexylamine were much less effective, 
requiring 5 mol % of the rhodium catalyst.  
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With Seth Ensign and Dr. Anil Gupta, the scope of the imine was explored next. Although 3.0 
equivalents was optimal for the PMP-imine substrate, 5.0 equivalents was found to be the most general 
across a variety of N-allylimines. Electron donating (149a, 150, and 155) and withdrawing groups (152, 
153, 154, and 156) on the imine were tolerated, although there was a moderate decrease in yield with p-
CF3- and p-MeO2C-substituents. The o-phenolic substrate (150) and the sterically encumbered mesityl 
substrate (151) react cleanly and quantitatively; the corresponding` amino imines could be obtained after 
filtration through basic alumina without the need for in situ reduction. Bromides, chlorides, and tertiary 
amines were also well tolerated under the reaction conditions. However, bis-o-dichloro substrate did not 
form any of the desired hydroamination product (157) Ketimines were able to be employed (158 and 159); 
however, higher catalyst loadings were required and the products were obtained in only modest yields after 
reduction. 
Next, the substitution on the allyl group was modified. The allylimine containing a 1,1-disubstituted 
olefin was successfully converted to the desired product (160). This allows for the formation of a tertiary 
C–N bond. Unfortunately, cis- and trans-1,2-disubstituted alkenes did not afford any of the hydroamination 
products, rather an undesired 1,3-hydride shift occurred to afford an enamine (Scheme 19).321,322 
Additionally, 1,1,2-trisubstituted alkene product 162 was not observed for the directed hydroamination. 
 
Next, substitution at the allylic position was explored.  Excitingly, the diastereoselectivities observed 
were all >10:1.  Using pyrrolidine, 11:1 d.r. was observed (163a), and >20:1 was observed with morpholine 
(163b). When using dimethylamine as the nucleophile, poor yield was obtained with high 
diastereoselectivity (163c). Cyclohexylamine could be employed to form the corresponding 1,2-diamine in 
modest yield and good diastereoselectivity (163d). It was found that these products were all the anti-1,2-
diamine as confirmed by x-ray diffraction (Figure 33 completed by Dr. Anil Gupta and Gregory Kortman). 
The relative configurations were confirmed by comparison to the literature using pyrrolidine as the 
nucleophile with the phenyl-substituted substrate (163a).323 
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Figure 33: X-ray crystal structure 
        
 
2.2.3. Secondary N-Allylamine Reaction Discovery and Optimization 
Having demonstrated N-allylimines can undergo Markovnikov-selective hydroamination, we sought to 
expand the scope of directing groups for this reaction. The ideal directing group would be one that is easily 
isolated and allow for the facile formation of 1,2-diamines.  As such, we sought to develop conditions that 
use secondary or and primary amine directing groups.  
Initial attempts by Dr. Anil Gupta resulted in poor yields when PMB protected allyl amine 170 and 
morpholine (144a) were employed (Scheme 20). It was observed that the starting material 170 was 
undergoing a 1,3-hydride shift to afford an enamine and imine under the reaction conditions. Moreover, a 
major byproduct resulting from the aldol condensation between imine and enamine, was observed. 
 
The reaction was optimized in order to slow the rate of isomerization relative to the hydroamination 
reaction and is summarized in Table 6 (performed by Dr. Anil Gupta). The desired product 149a was 
initially afforded in only 12% yield (Table 6, entry 1). Changing the ligand provided the most dramatic 
improvements in the reaction; BINAP facilitated the hydroamination reaction with an NMR yield of 40% 
(Table 6, entry 2). Increasing the flexibility and decreasing the bite angle lead to significant improvements, 
as dppp and dppb afford 149a in 62% and 64%, respectively (Table 6, entries 4 and 5). A further increase 
in yield to 70% was observed upon using DME as the solvent (Table 6, entry 5). Smaller bite angle ligands 
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(dppe) and larger bite angle ligands 
(dpppent and dpph) were much less 
effective. Compared to the imine reaction, 
dppb was employed rather than DPEphos, 
DME was used as a solvent instead of 
MeCN, and 5% catalyst instead of 1% was 
sufficient to increase yields and reducing 
byproduct formation. Excitingly, this 
hydroamination reaction favors an 
intermolecular reaction over the 
corresponding intramolecular 1,3-hydride 
shift known with tertiary N-
allylamines.321,322 
While secondary allylic amines are 
competent substrates for the hydroamination 
reaction, they remain some of the most 
difficult.  First, 7.0 equiv of the nucleophile 
generally required to obtain the product in good yields (Table 7). This was demonstrated for a variety of 
cyclic, secondary amine nucleophiles.  Second, these reactions require far higher catalyst loading (5 mol % 
of catalyst) for the reaction to go to completion in 24 hours (performed by Dr. Anil Gupta) compared to the 
imine hydroamination. 
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2.2.4. Secondary N-Allylamine Substrate Scope 
In terms of reaction scope, the scope of 
the amine nucleophile with secondary allylic 
amines was determined.  As shown in Table 
8, cyclic secondary amines are incorporated 
in good yields. Other secondary allylic 
amines were reactive under the optimized 
conditions to afford good yields of the 1,2-
diamines. Aryl bromides (154), thiophene 
(172), geranyl (173), and cyclohexyl (159) 
groups were all successfully employed in 
generating the corresponding 1,2-diamines. 
1,1-disubstituted (160) and allylic substituted 
(174) substrates were not amenable, as the 
1,3-hydride shift dominated. Additionally, 
mono- and bis-aryl ketones (158 and 175) 
were not tolerated as the 1,3-hydride shift 
was the major competing reaction. This 
substitution proximal to the amine directing-
group proved to inhibit the desired-reaction 
from occurring. 
 
2.2.5. Primary N-Allylamine Reaction 
Discovery and Optimization 
As previously mentioned, 
cyclohexanamine undergoes imine exchange 
with the starting material, releasing allyl 
amine into the solution when the N-allylimine 
is utilized as the substrate. Because of this, it 
was questioned if allylamine itself is a 
competent directing group for the 
hydroamination. Under nearly identical 
conditions to the imine reaction (increasing 
catalyst loading from 1 mol % to 2 mol %), 
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allylamine was able to undergo the hydroamination with morpholine to form desired product 177 (Scheme 
21). 
 
Seeking to develop conditions that allow for lower catalyst and nucleophile loading, we reasoned that 
primary amines would be the ideal directing groups; these should be significantly less hindered.  However, 
one anticipated challenge was that the substrate could undergo an intermolecular hydroamination with itself.  
However, this was not observed under standard reaction conditions. A significant amount of the 1,3-hydride 
shift byproduct was observed instead (Scheme 22). We found that by changing the ligand to DPEphos, and 
using the optimized conditions for allyl imine substrates, an 87% yield could be obtained in the 
hydroamination of allylamine with morpholine after 24 hours.  
Scheme 22: Byproduct formation 
 
To further optimize, a time study was conducted under the previously optimized conditions; it was 
found that the reaction was complete after 30 minutes with 5.0 equivalents of morpholine and 2 mol % of 
the rhodium catalyst. However, upon lowering the equivalents of morpholine from 5.0 to 2.0, the reaction 
only took 2 hours at 60 °C to reach completion. 
 
2.2.6. Primary N-Allylamine Substrate Scope 
Gratifyingly, high diastereoselectivities were observed when 1-phenylallylamine was employed (177). 
An 84% yield (>20:1 d.r.) was obtained of the desired 1,2-diamine. Similar functional group tolerance to 
the allyl imine hydroamination was also observed. Aryl bromides (168), trifluoromethyl (179), methoxy 
groups (166), and chlorides (180) were amenable to the reaction in very good yields. Aliphatic 
substitution showed similar reactivity, but lower diastereoselectivities were obtained (181, 164). When  
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comparing to those obtained for the allyl imine-directed hydroamination, slightly lower 
diastereoselectivities were obtained in most cases as exemplified by the phenethyl substituted substrate 
(164) where a 73% isolated yield (16:1 d.r.) was obtained when using the PMP-imine. When using the 
phenethyl-substituted allyl amine, a 73% isolated yield (13:1 d.r.) was obtained. Note: Table 9 was 
completed with Dr. Anil Gupta. 
The allyl amine hydroamination reaction was also investigated using a chiral substrate (Scheme 23). 
No loss in enantioselectivity was observed after the hydroamination suggesting that isomerization of the 
starting material does not lead to the desired product. 
 
Lastly, in an effort to expand the nucleophile scope for the developed hydroamination reactions, 
secondary acyclic and primary amine nucleophiles were investigated. Dimethylamine and 
methylbenzylamine afforded the 1,2-diamine in 74% (182) and 33% (183) isolated yield, respectively. 
Dimethylamine was considerably lower yielding (22%) when the allylic substituted imine was employed. 
Unfortunately, no product is observed when diethylamine is employed under the reaction conditions. 
Excitingly, we found that primary amines were also able to undergo the desired hydroamination with 
primary allylamine directing groups. Our studies began by using cyclohexylamine as the nucleophile. It 
was found that excess nucleophile was required; 5.0 equivalents of cyclohexylamine was found to be 
required along with higher catalyst loadings (7.5 mol %) (Table 8, 188). To our knowledge, this is the first 
example of an intermolecular hydroamination catalyzed by rhodium that can employ primary aliphatic 
amine nucleophiles.  
Other primary aliphatic amines, butylamine (185), iso-butylamine (186), and isopropylamine (187) 
showed similar reactivity and high diastereoselectivity (>20:1) in most cases. The 1,2-diamine and 1,2-
aminoether were effective nucleophiles, affording (189) and (190) in 55% and 71% yield, respectively. 
Interestingly, cyclohexanamine gave a 9:1 d.r. which is slightly lower than the 12:1 d.r. when the imine 
was used as the directing group. 
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2.2.7. Mechanistic Studies 
With the discovery of allylamine derivatives as competent functional groups for the hydroamination, it 
was questioned if the imine directing group was undergoing exchange, releasing allylamine into solution 
through reaction with morpholine. Our method of study was to perform cross-over experiments using 
different imine directing groups. We observed that imines 191 and 192 readily exchange with stirring in 
MeCN, without addition of nucleophile or catalyst to give a statistical mixture of products 193a, 193b, 
193c, and 193d. This suggests that it is possible for the corresponding allylamine to be exchanged (Scheme 
24).  
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Ketimines are more stable than aldimines. Therefore, in the presence of both a ketone and an aldehyde, 
imine formation should selectively occur with the aldehyde. If labializing the allyl amine from the imine is 
required prior to the Rh-catalyzed hydroamination reaction, then when ketamine 143 is subjected to the 
hydroamination conditions in the presence of added aldehyde, the aldimine product should be formed 
selectively. However, when ketimine 143 was subjected to the hydroamination conditions in the presence 
of 4-methoxybenzaldehyde, 145 was the only hydroamination product observed (Scheme 25). Further, 
when aldimine 147 was used as the substrate, no exchange was observed with the addition of benzophenone 
(Scheme 26). Combined, these experiments indicate that N-allyl imines can undergo the hydroamination, 
but does not preclude the fact that N-allyl amines may also be undergoing the hydroamination reaction 
simultaneously when aldimines are employed while ketimines undergo the hydroamination reaction 
directly. 
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These two experiments suggest that when the ketimine is employed under reaction conditions, the imine 
is in fact the directing group for the hydroamination reaction. In the case of aldimines, it cannot be ruled 
out that allylamine is the directing group for the reaction through an exchange reaction. 
Next, preliminary mechanistic data was obtained by Dr. Anil Gupta by using deuterated 
tetrahydroisoquinoline as the nucleophile in the imine reaction. The deuterium was exclusively transferred 
to the terminal position of the olefin. This suggests that β-hydride elimination-reinsertion from the 
metallacyclic intermediate is slow relative to C–D bond formation (Scheme 27). 
 
Based on literature precedence3,324,325 and our deuterium incorporation study, the following catalytic 
cycle (Figure 34): 1) the allylimine coordinates to the rhodium (I) catalyst, 2) the cyclic secondary amine 
nucleophile undergoes an outer-sphere aminometallation, 3) Then, proton transfer to generated a Rh-H 
followed by reductive elimination or direct protolytic cleavage generates the product-bound metallacycle, 
and 4) Ligand exchange re-enters the catalytic cycle. The metallacyclic intermediate is proposed to form 
during the reaction; therefore, it was hypothesized that aminometallation would lead to a highly 
diastereoselective reaction due to strain built up in the transition-state. 
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2.3. Conclusions and Outlook 
A highly regio-, chemo-, and diastereoselective intermolecular, rhodium-catalyzed hydroamination 
reaction has been realized. This represents significant progress in intermolecular hydroamination 
reactions where the direct addition of N–H across an olefin is possible. Allylimines, secondary 
allylamines, and primary allylamines proved to be excellent directing groups for this reaction in high 
diastereoselectivities. Additionally, the nucleophile scope was significantly improved by utilizing 
secondary cyclic, secondary acyclic, and primary amine nucleophiles, representing one of the only 
hydroamination reactions that enable the use of such nucleophiles broadly. A better understanding of the 
reaction mechanism via several mechanistic experiments is currently being pursued. Additionally, it 
would be extremely useful to enable an asymmetric version of this reaction. Currently, the best result has 
been a 5:1 enantiomeric ratio and is being pursued further in the Hull lab (Scheme 28). 
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CHAPTER 3* 
Experimental 
3.1. General Information 
General Experimental Procedures: All reactions were carried out in flame-dried (or oven-dried at 140 
°C for at least 2 h) glassware under an atmosphere of nitrogen unless otherwise indicated. Nitrogen was 
dried using a drying tube equipped with Drierite™ unless otherwise noted. Air- and moisture-sensitive 
reagents were handled in a nitrogen-filled glovebox (working oxygen level ~ 0.1 ppm).  Column 
chromatography was performed with silica gel from Grace Davison Discovery Sciences (35-75 μm) with a 
column mixed as a slurry with the eluent and was packed, rinsed, and run under air pressure. Alternatively, 
automated columns were performed using a Teledyne ISCO system, employing either Biotage® SNAP Dry 
Load cartridges (loaded under suction with Davisil Chromatographic Silica Media 35-70 micron mesh), 
ValueBrand Silica Flash Chromatography Columns purchased from Practichem, or end capped cyano 
RediSep®Rf Gold columns (20-40 micron mesh) purchased from Teledyne Isco. Samples were eluted using 
a flow rate of 18–40 mL/min, with detection by UV (254 nm or 280 nm). Analytical thin-layer 
chromatography (TLC) was performed on precoated glass silica gel plates (by EMD Chemicals Inc.) with 
F-254 indicator. Visualization was either by short wave (254 nm) ultraviolet light, or by staining with 
potassium permanganate followed by brief heating on a hot plate or by a heat gun. Distillations were 
performed using a 3 cm short-path column under reduced pressure or by using a Hickman still at ambient 
pressure. 
Instrumentation: 1H NMR and 13C NMR were recorded on a Varian Unity 400/500 MHz (100/125 MHz 
respectively for 13C) or a VXR-500 MHz spectrometer. Spectra were referenced using either CDCl3 or C6D6 
as solvents (unless otherwise noted) with the residual solvent peak as the internal standard (1H NMR: δ 7.26 
ppm, 13C NMR: δ 77.00 ppm for CDCl3 and 1H NMR: δ 7.15 ppm, 13C NMR: δ 128.60 ppm for C6D6). 
Chemical shifts were reported in parts per million and multiplicities are as indicated: s (singlet,) d (doublet,) 
t (triplet,) q (quartet,) p (pentet,) m (multiplet,) and br (broad). Coupling constants, J, are reported in Hertz 
and integration is provided, along with assignments, as indicated. Analysis by Gas Chromatography-Mass 
Spectrometry (GC-MS) was performed using a Shimadzu GC-2010 Plus Gas chromatograph fitted with a 
Shimadzu GCMS-QP2010 SE mass spectrometer using electron impact (EI) ionization after analytes 
traveled through a SHRXI–5MS- 30m x 0.25 mm x 0.25 μm column using a helium carrier gas.  Data are 
reported in the form of m/z (intensity relative to base peak = 100). Gas Chromatography (GC) was 
performed on a Shimadzu GC-2010 Plus gas chromatograph with SHRXI–MS- 15m x 0.25 mm x 0.25 μm 
column with nitrogen carrier gas and a flame ionization detector (FID). Low-resolution Mass Spectrometry  
 
* This section includes previously published material319 
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and High Resolution Mass Spectrometry were performed in the Department of Chemistry at University of 
Illinois at Urbana-Champaign. The glove box, MBraun LABmaster sp, was maintained under nitrogen 
atmosphere. Melting points were recorded on a Thomas Hoover capillary melting point apparatus and are 
uncorrected. 
Materials: Solvents used for extraction and column chromatography were reagent grade and used as 
received. Reaction solvents tetrahydrofuran (Fisher, unstabilized HPLC ACS grade), diethyl ether (Fisher, 
BHT stabilized ACS grade), methylene chloride (Fisher, unstabilized HPLC grade), dimethoxyethane 
(Fisher, certified ACS), toluene (Fisher, optima ACS grade), 1,4-dioxane (Fisher, certified ACS), 
acetonitrile (Fisher, HPLC grade), and hexanes (Fisher, ACS HPLC grade) were dried on a Pure Process 
Technology Glass Contour Solvent Purification System using activated Stainless Steel columns while 
following manufacture’s recommendations for solvent preparation and dispensation unless otherwise noted. 
All amines (excluding allyl amine) were distilled and degassed by the freeze-pump-thaw method, and were 
stored over 4 Å molecular sieves under an atmosphere of nitrogen in glove box before use. Allylamine 10 
was obtained from Aldrich Chemical Co., Inc. and used as received. All liquid aldehydes were distilled 
prior to use, and ketones, benzophenone and cyclohexanone, were used as received.  
 
3.2. Experimental Procedures of Chapters 2.2.1 and 2.2.2 
A. General Procedure for Screening Reactions with no stock solutions 
In the glove box, to a 4 mL scintillation vial fitted with a magnetic stir bar was added [Rh(COD)Cl]2 
(1.0 equiv.), followed by the silver salt (2.0 equiv.) and phosphine ligand (2.0 equiv.). Dry solvents were 
added next followed by the imine substrate. Lastly, morpholine as well as 1-methylnapthalene (10 μL, 0.071 
mmol) were added, and the vial was capped with Teflon-sealed cap. This was taken outside of the glove 
box and heated to the desired temperature overnight. 
B. General Procedure for Screening Reactions with stock solutions 
In the glove box, if n equivalents of each substance is needed for the desired amount of screens, n+1 
equivalents were used in each case. In a 20 mL scintillation vial fitted with a magnetic stir bar was added 
[Rh(COD)Cl]2 (1.0 equiv.), followed by the silver salt (2.0 equiv.) and phosphine ligand (2.0 equiv.). Dry 
solvents were added next followed by the imine substrate. This was stirred for 15 minutes, dissolving all of 
the rhodium catalyst while precipitating the silver salt. Next, morpholine as well as 1-methylnapthalene 
were added and was aliquatted equally (total volume/n+1) into 4 mL scintillation vials fitted with magnetic 
stir bars. If drying agents were used, they were added at this stage as well as any base. The vials were 
capped with Teflon-sealed caps, were taken out of the glove box, and were heated overnight. 
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Calibration Curve for (E)-N-allyl-1-(4-methoxyphenyl)methanimine (148) 
Screening reactions were diluted and stirred in 4M HCl (2 mL) after removing morpholine on high 
vacuum for 3 hours. The resulting aqueous layer was washed with CH2Cl2. The aqueous layer was basified 
with NaOH pellets and was washed with CHCl3 (3 x 50 mL). The combined organic layers were dried over 
MgSO4, filtered, and rotary evaporated to yield the hydrolyzed 1,2-diamine (0.144g, 1.00 mmol). To this 
was added p-methoxybenzaldehyde (135 mg, 1.00 mmol, 1.0 equiv.) to yield imine (148) as a yellow oil 
and was used for the calibration curve.1-methylnapthalene was used as the standard for all screens. The 
data for the curve can be seen below.  
1H-NMR (400 MHz; Benzene): δ 8.01 (s, 1H), 7.75 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 3.73 (ddd, 
J = 11.4, 4.9, 1.3 Hz, 1H), 3.63 (t, J = 4.6 Hz, 4H), 3.38 (ddd, J = 11.4, 7.8, 1.3 Hz, 1H), 3.22 (s, 3H), 2.90-
2.81 (m, 1H), 2.43 (q, J = 3.7 Hz, 4H), 1.06 (d, J = 6.7 Hz, 3H) ppm. 
 
C. General Allyl Imine Hydroamination Procedure A: 
 
[(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), imine (259 μL, 1.50 mmol, 1.00 equiv.), 
amine nucleophile, and dry CH3CN (350 μL) were added to an oven-dried 4 mL vial equipped with a stir 
bar in the glove box. The resulting solution was allowed to stir for 24 h at 60 °C. In an oven-dried 25 mL 
round bottom flask was added NaBH4 (57 mg, 2.3 mmol, 1.5 equiv.) and MeOH (3 mL) and cooled to 0 
°C. The solution of the aminoimine in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). 
The reaction was brought to room temperature, stirred for 2 h, and then concentrated in vacuo. The residue 
was dissolved with CHCl3 (20 mL) and washed with saturated NaHCO3 (15 mL). The organic layer was 
separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were combined, 
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dried over anhydrous MgSO4, and filtered. The solution was concentrated in vacuo followed by drying 
under high vacuum (0.05 mm Hg) for 1 h to afford crude diamine. Purification by silica gel chromatography 
(125 mL silica, 3% NH4OH : 3% MeOH : 94% CHCl3 v/v prepared by extracting saturated NH4OH with 
CHCl3, removing aqueous layer, and adding methanol) afforded pure diamine. 
 
D. Control Experiments and Optimization 
Under the optimized reaction conditions, in the presence of [(DPEphos)Rh(COD)]BF4 148 is afforded in 
98% GC yield. 
 
Under the optimized reaction conditions, in the absence of [(DPEphos)Rh(COD)]BF4 148 is afforded in 
0% GC yield; no reaction is observed by GC. 
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Table 11: Silver salt screens in various solvents 
 
Silver Salt Solvent Yield  Silver Salt Solvent Yield 
AgBF4 neat 26  AgSO3CF3 Toluene 8 
AgOAc neat 6  AgPF6 Toluene 8 
AgF neat 8  AgTFA Toluene 1 
AgSbF6 neat 23  AgSO3CH3 Toluene 2 
AgSO3CF3 neat 18  AgSO3C7H7 Toluene 4 
AgPF6 neat 19  AgBF4 DME 12 
AgTFA neat 27  AgSbF6 DME 10 
AgSO3CH3 neat 29  AgSO3CF3 DME 8 
AgSO3C7H7 neat 24  AgPF6 DME 8 
AgBF4 1,4-Dioxane 24  AgTFA DME 2 
AgOAc 1,4-Dioxane 3  AgSO3CH3 DME 2 
AgF 1,4-Dioxane 1  AgSO3C7H7 DME 2 
AgSbF6 1,4-Dioxane 28  AgBF4 THF 18 
AgSO3CF3 1,4-Dioxane 33  AgSbF6 THF 10 
AgPF6 1,4-Dioxane 29  AgSO3CF3 THF 15 
AgTFA 1,4-Dioxane 18  AgPF6 THF 9 
AgSO3CH3 1,4-Dioxane 19  AgTFA THF 2 
AgSO3C7H7 1,4-Dioxane 14  AgSO3CH3 THF 5 
AgBF4 Benzene 4  AgSO3C7H7 THF 2 
AgSbF6 Benzene 5  AgBF4 Acetonitrile 11 
AgSO3CF3 Benzene 6  AgSbF6 Acetonitrile 12 
AgPF6 Benzene 1  AgSO3CF3 Acetonitrile 8 
AgTFA Benzene 2  AgPF6 Acetonitrile 10 
AgSO3CH3 Benzene 4  AgTFA Acetonitrile 4 
AgSO3C7H7 Benzene 3  AgSO3CH3 Acetonitrile 3 
AgBF4 Toluene 5  AgSO3C7H7 Acetonitrile 4 
AgSbF6 Toluene 7     
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Table 12: Morpholine equivalency screens with various silver salts and solvents 
 
Silver Salt Morpholine Equiv Solvent Yield 
AgSO3CF3 1 1,4-Dioxane 18 
AgSO3CF3 2 1,4-Dioxane 28 
AgSO3CF3 3 1,4-Dioxane 40 
AgSO3CF3 4 1,4-Dioxane 42 
AgSO3CF3 5 1,4-Dioxane 36 
AgSO3CF3 10 1,4-Dioxane 26 
AgPF6 1 1,4-Dioxane 22 
AgPF6 2 1,4-Dioxane 32 
AgPF6 3 1,4-Dioxane 42 
AgPF6 4 1,4-Dioxane 43 
AgPF6 5 1,4-Dioxane 24 
AgPF6 10 1,4-Dioxane 43 
AgSbF6 1 1,4-Dioxane 22 
AgSbF6 2 1,4-Dioxane 16 
AgSbF6 3 1,4-Dioxane 40 
AgSbF6 4 1,4-Dioxane 45 
AgSbF6 5 1,4-Dioxane 41 
AgSbF6 10 1,4-Dioxane 45 
AgBF4 1 1,4-Dioxane 24 
AgBF4 2 1,4-Dioxane 34 
AgBF4 3 1,4-Dioxane 42 
AgBF4 4 1,4-Dioxane 42 
AgBF4 5 1,4-Dioxane 54 
AgBF4 10 1,4-Dioxane 13 
AgBF4 1 DME 18 
AgBF4 2 DME nd 
AgBF4 3 DME 39 
AgBF4 4 DME 46 
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Table 12 (cont.): 
Silver Salt Morpholine Equiv Solvent Yield 
AgBF4 5 DME 44 
AgBF4 10 DME 42 
AgBF4 1 THF 17 
AgBF4 2 THF 30 
AgBF4 3 THF 34 
AgBF4 4 THF 41 
AgBF4 5 THF 44 
AgBF4 10 THF 45 
AgSbF6 1 Acetonitrile 13 
AgSbF6 2 Acetonitrile 33 
AgSbF6 3 Acetonitrile 45 
AgSbF6 4 Acetonitrile 52 
AgSbF6 5 Acetonitrile 52 
AgSbF6 10 Acetonitrile 49 
AgSO3CF3 10 Benzene 64 
AgPF6 10 Toluene 51 
AgSbF6 10 DME 44 
AgSO3CF3 10 THF 63 
AgBF4 10 Acetonitrile 49 
AgPF6 10 Acetonitrile 54 
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Table 13: Catalyst loading screens with various silver salts, solvents, and equivalents of morpholine 
 
Silver Salt Morpholine Equiv Catalyst Loading Solvent Yield 
AgSO3CF3 3 0.25 1,4-Dioxane 24 
AgSO3CF3 3 0.50 1,4-Dioxane 29 
AgSO3CF3 3 1.00 1,4-Dioxane 55 
AgSO3CF3 3 1.50 1,4-Dioxane 61 
AgSO3CF3 3 2.00 1,4-Dioxane 68 
AgBF4 5 0.25 1,4-Dioxane 10 
AgBF4 5 0.50 1,4-Dioxane 35 
AgBF4 5 1.00 1,4-Dioxane 63 
AgBF4 5 1.50 1,4-Dioxane 68 
AgBF4 5 2.00 1,4-Dioxane 66 
AgBF4 4 0.25 DME 12 
AgBF4 4 0.50 DME 47 
AgBF4 4 1.00 DME 65 
AgBF4 4 1.50 DME 72 
AgBF4 4 2.00 DME 71 
AgSbF6 4 0.25 Acetonitrile 30 
AgSbF6 4 0.50 Acetonitrile 44 
AgSbF6 4 1.00 Acetonitrile 65 
AgSbF6 4 1.50 Acetonitrile 69 
AgSbF6 4 2.00 Acetonitrile 65 
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Table 14: Concentration screens with various silver salts and equivalents of morpholine using a stock 
solution 
 
Silver Salt Morpholine Equiv Concentration (M) Yield 
AgBF4 6 3.8 84 
AgBF4 6 1.9 78 
AgBF4 6 1.3 72 
AgBF4 6 0.95 67 
AgBF4 6 0.76 64 
AgBF4 6 0.63 59 
AgSO3CF3 9 3.8 80 
AgSO3CF3 9 1.9 75 
AgSO3CF3 9 1.3 73 
AgSO3CF3 9 0.95 51 
AgSO3CF3 9 0.76 66 
AgSO3CF3 9 0.63 58 
AgPF6 10 3.8 75 
AgPF6 10 1.9 73 
AgPF6 10 1.3 70 
AgPF6 10 0.95 67 
AgPF6 10 0.76 68 
AgPF6 10 0.63 61 
AgSbF6 8 3.8 76 
AgSbF6 8 1.9 74 
AgSbF6 8 1.3 66 
AgSbF6 8 0.95 66 
AgSbF6 8 0.76 61 
AgSbF6 8 0.63 58 
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Table 15: Screens with base and silver salts and equivalents of morpholine 
 
Silver Salt Morpholine Equiv Base Base Equiv Solvent Yield 
AgBF4 8 Et3N 1 1,4-Dioxane 68 
AgBF4 8 Et3N 0.1 1,4-Dioxane 77 
AgBF4 8 Na2CO3 1 1,4-Dioxane 82 
AgBF4 8 Na2CO3 0.1 1,4-Dioxane 79 
AgBF4 8 K2CO3 1 1,4-Dioxane 14 
AgBF4 8 K2CO3 0.1 1,4-Dioxane 72 
AgBF4 8 Cs2CO3 1 1,4-Dioxane 1 
AgBF4 8 Cs2CO3 0.1 1,4-Dioxane 0 
AgBF4 8 none none 1,4-Dioxane 76 
AgSO3CF3 8 Et3N 1 1,4-Dioxane 72 
AgSO3CF3 8 Et3N 0.1 1,4-Dioxane 76 
AgSO3CF3 8 Na2CO3 1 1,4-Dioxane 83 
AgSO3CF3 8 Na2CO3 0.1 1,4-Dioxane 80 
AgSO3CF3 8 K2CO3 1 1,4-Dioxane 60 
AgSO3CF3 8 K2CO3 0.1 1,4-Dioxane 80 
AgSO3CF3 8 Cs2CO3 1 1,4-Dioxane 4 
AgSO3CF3 8 Cs2CO3 0.1 1,4-Dioxane 19 
AgSO3CF3 8 none none 1,4-Dioxane 76 
AgPF6 6 Et3N 1 1,4-Dioxane 66 
AgPF6 6 Et3N 0.1 1,4-Dioxane 65 
AgPF6 6 Na2CO3 1 1,4-Dioxane 69 
AgPF6 6 Na2CO3 0.1 1,4-Dioxane 66 
AgPF6 6 K2CO3 1 1,4-Dioxane 60 
AgPF6 6 K2CO3 0.1 1,4-Dioxane 70 
AgPF6 6 Cs2CO3 1 1,4-Dioxane 1 
AgPF6 6 Cs2CO3 0.1 1,4-Dioxane 11 
AgPF6 6 none none 1,4-Dioxane 62 
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Table 15 (cont.): 
Silver Salt Morpholine Equiv Base Base Equiv Solvent Yield 
AgSbF6 6 Et3N 1 1,4-Dioxane 57 
AgSbF6 6 Et3N 0.1 1,4-Dioxane 61 
AgSbF6 6 Na2CO3 1 1,4-Dioxane 54 
AgSbF6 6 Na2CO3 0.1 1,4-Dioxane 58 
AgSbF6 6 K2CO3 1 1,4-Dioxane 58 
AgSbF6 6 K2CO3 0.1 1,4-Dioxane 58 
AgSbF6 6 Cs2CO3 1 1,4-Dioxane 0 
AgSbF6 6 Cs2CO3 0.1 1,4-Dioxane 27 
AgSbF6 6 none none 1,4-Dioxane 60 
AgBF4 6 Et3N 1 Acetonitrile 80 
AgBF4 6 Et3N 0.1 Acetonitrile 79 
AgBF4 6 Na2CO3 1 Acetonitrile 87 
AgBF4 6 Na2CO3 0.1 Acetonitrile 81 
AgBF4 6 K2CO3 1 Acetonitrile n/a 
AgBF4 6 K2CO3 0.1 Acetonitrile 0 
AgBF4 6 Cs2CO3 1 Acetonitrile 58 
AgBF4 6 Cs2CO3 0.1 Acetonitrile 2 
AgBF4 6 none none Acetonitrile 73 
AgSO3CF3 9 Et3N 1 Acetonitrile 80 
AgSO3CF3 9 Et3N 0.1 Acetonitrile 77 
AgSO3CF3 9 Na2CO3 1 Acetonitrile 81 
AgSO3CF3 9 Na2CO3 0.1 Acetonitrile 80 
AgSO3CF3 9 K2CO3 1 Acetonitrile 55 
AgSO3CF3 9 K2CO3 0.1 Acetonitrile 78 
AgSO3CF3 9 Cs2CO3 1 Acetonitrile 1 
AgSO3CF3 9 Cs2CO3 0.1 Acetonitrile 10 
AgSO3CF3 9 none none Acetonitrile 74 
AgPF6 10 Et3N 1 Acetonitrile 75 
AgPF6 10 Et3N 0.1 Acetonitrile 75 
AgPF6 10 Na2CO3 1 Acetonitrile 75 
AgPF6 10 Na2CO3 0.1 Acetonitrile 76 
AgPF6 10 K2CO3 1 Acetonitrile 39 
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Table 15 (cont.): 
Silver Salt Morpholine Equiv Base Base Equiv Solvent Yield 
AgPF6 10 K2CO3 0.1 Acetonitrile 70 
AgPF6 10 Cs2CO3 1 Acetonitrile 2 
AgPF6 10 Cs2CO3 0.1 Acetonitrile 9 
AgPF6 10 none none Acetonitrile 78 
AgSbF6 8 Et3N 1 Acetonitrile 75 
AgSbF6 8 Et3N 0.1 Acetonitrile 76 
AgSbF6 8 Na2CO3 1 Acetonitrile 76 
AgSbF6 8 Na2CO3 0.1 Acetonitrile 78 
AgSbF6 8 K2CO3 1 Acetonitrile 69 
AgSbF6 8 K2CO3 0.1 Acetonitrile 75 
AgSbF6 8 Cs2CO3 1 Acetonitrile 1 
AgSbF6 8 Cs2CO3 0.1 Acetonitrile 28 
 
 
Table 16: Screens with various drying agents 
 
Drying Agent Yield 
3 Å Mol. Powder 88 
4 Å Mol. Powder 88 
5 Å Mol. Powder 90 
4 Å Mol. Sieves 85 
MgSO4 86 
none 88 
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Table 17: Temperature screens with different equivalents of morpholine 
 
Temperature Morpholine Equiv Yield 
rt 1 28 
rt 2 39 
rt 3 46 
rt 4 37 
30 1 33 
30 2 47 
30 3 55 
30 4 50 
40 1 19 
40 2 42 
40 3 55 
40 4 67 
50 1 47 
50 2 71 
50 3 83 
50 4 83 
60 1 47 
60 2 73 
60 3 85 
60 4 88 
70 1 39 
70 2 70 
70 3 79 
70 4 84 
80 1 29 
80 2 65 
80 3 78 
80 4 79 
64 
 
E. Experimental Procedure, Isolation, and Characterization 
Note: All allyl imines were prepared according to the published literature procedure319 analogous to the 
synthesis of 147 below. 
 
 
(E)-N-allyl-1-(4-methoxyphenyl)methanimine, 147: p-Anisaldehyde (30 mL, 250 mmol, 1.0 equiv.), 4 Å 
MS (10.0 g, beads) and dry CH2Cl2 (100 mL) were added to a 500 mL round bottom flask with a stir bar 
followed by allylamine (27 mL, 370 mmol, 1.5 equiv.). The reaction mixture was placed under N2 and 
stirred at room temperature for 24 h. It was filtered through Celite, washing with CH2Cl2 (120 mL). The 
filtrate was washed with water (200 mL  2) and brine (200 mL  1). The organic layer was dried with 
MgSO4, filtered, and concentrated under reduced pressure to give imine 147 as a pale yellow oil in 84% 
yield (36 g, 210 mmol). The imine was used without further purification. 
1H NMR (C6D6, 500 MHz): δ 7.92 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 8.7 Hz, 2H), 6.04 (ddt, J 
= 17.1, 10.2, 5.5 Hz, 1H), 5.23 (dd, J = 17.1, 1.9 Hz, 1H), 5.04 (dd, J = 10.3, 1.8 Hz, 1H), 4.17 – 3.93 (m, 
2H), 3.22 (s, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 161.87, 160.47, 136.96, 129.95, 129.90, 115.17, 114.10, 63.57, 54.70 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C11H14NO, 176.1075; found: 176.1074.  
 
N-(4-methoxybenzyl)-2-morpholinopropan-1-amine, 149a: 
[(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), imine 147 (259 
μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were added to an 
oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added morpholine, 144a (390 μL, 4.5 mmol, 3.0 equiv.). The resulting solution was 
allowed to stir for 24 h at 60 °C. To an oven-dried 25 mL round bottom flask was added NaBH4 (57 mg, 
2.3 mmol, 1.5 equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was 
added dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, 
stirred for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed 
with saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4, and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 149a as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
3% NH4OH : 3% MeOH : 94% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
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aqueous layer, and adding methanol) afforded pure diamine 149a as a pale yellow oil in 82% yield (323 
mg, 1.22 mmol).  
Rf  = 0.55 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ  7.25 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 3.66 (d, J = 12.9 Hz, 1H), 
3.64 (d, J = 13.1 Hz, 1H), 3.49 (qdd, J = 11.3, 6.4, 3.3 Hz, 4H), 3.29 (s, 3H), 2.54 (dqd, J = 8.3, 6.6, 4.9 
Hz, 1H), 2.43 (dd, J = 11.6, 8.4 Hz, 1H), 2.33 (dd, J = 11.6, 4.9 Hz, 1H), 2.21 (ddd, J = 10.5, 6.5, 3.5 Hz, 
2H), 2.07 (ddd, J = 10.6, 6.6, 3.6 Hz, 2H) 1.55 (br s, 1H), 0.70 (d, J = 6.4 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 159.0, 133.5, 129.3, 113.9, 67.4, 58.9, 54.7, 53.6, 51.6, 48.8, 11.7 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O2, 265.1916; found, 265.1906.  
 
N-(4-methoxybenzyl)-2-(piperidin-1-yl)propan-1-amine, 149b: 
[(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), imine 147 (259 
μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added piperidine (185 μL, 2.25 mmol, 1.50 equiv.). The resulting solution was allowed to stir 
for 24 h at 60 °C. To an oven-dried 25 mL round bottom flask was added NaBH4 (57 mg, 2.3 mmol, 1.5 
equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added 
dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, stirred 
for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with 
saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 149b as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
3% NH4OH : 3% MeOH : 94% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 149b as a pale yellow oil in 87% yield (340 
mg, 1.3 mmol).  
Rf  = 0.63 (1:9 NH4OH/CHCl3).   
1H NMR (C6D6, 500 MHz): δ  7.28 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 8.4 Hz, 2H), 3.72 (d, J = 13.2 Hz, 1H), 
3.68 (d, J = 13.0 Hz, 1H), 3.28 (s, 3H), 2.77-2.70 (dqd, J = 9.2, 6.6, 4.7, 1H), 2.52 (dd, J = 11.3, 9.4 Hz, 
1H), 2.39 (dd, J = 11.4, 4.8 Hz, 1H), 2.33 (ddd, J = 10.8, 7.3, 3.4 Hz, 2H), 2.14 (t, J = 7.1 Hz, 2H), 1.86 (s, 
1H), 1.44-1.37 (m, 4H), 1.29-1.22 (m, 2H), 0.74 (d, J = 6.6 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 159.0, 133.7, 129.4, 113.9, 59.2, 54.7, 53.6, 52.2, 49.3, 26.9, 25.3, 11.3 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H27N2O, 263.2123; found, 263.2130.  
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N-(4-methoxybenzyl)-2-(4-methylpiperazin-1-yl)propan-1-  
amine, 149c: [(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), 
imine 147 (259 μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were 
added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. 
To the reaction mixture was added 1-methylpiperazine (749 μL, 6.75 mmol, 4.00 equiv.). The resulting 
solution was allowed to stir for 24 h at 60 °C. To the vial was added p-anisaldehyde (91 μL, 0.75 mmol, 
0.50 equiv.) and the mixture was stirred for 2 hours.  To an oven-dried 25 mL round bottom flask was added 
NaBH4 (57 mg, 2.3 mmol, 1.5 equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine 
in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room 
temperature, stirred for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) 
and washed with saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was 
extracted with CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and 
filtered. The solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 
1 h to afford crude 149c as a yellow oil. Purification of the crude diamine by silica gel chromatography 
(125 mL silica, 3% NH4OH : 3% MeOH : 94% CHCl3 v/v prepared by extracting saturated NH4OH with 
CHCl3, removing aqueous layer, and adding methanol) afforded pure diamine 149c as a pale yellow oil in 
66% yield (274 mg, 0.988 mmol).  
Rf  = 0.42 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ  7.27 (d, J = 8.7 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 3.70 (d, J = 13.1 Hz, 1H), 
3.67 (d, J = 13.2 Hz, 1H), 3.29 (s, 3H), 2.70 (dqd, J = 8.7, 6.7, 4.8 Hz, 1H), 2.49 (dd, J = 11.6, 8.8 Hz, 1H), 
2.46-2.42 (m, 2H), 2.39 (dd, J = 11.6, 4.9 Hz, 1H), 2.30-2.15 (m, 6H), 2.08 (s, 3H), 1.76 (s, 1H), 0.76 (d, J 
= 6.6 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 159.0, 133.7, 129.3, 113.9, 58.5, 55.9, 54.7, 54.7, 53.6, 52.1, 46.2, 11.7 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H28N3O, 278.2232; found, 278.2228. 
 
2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(4-methoxybenzyl)propan-1- 
amine, 149d: [(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), 
imine 147 (259 μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were 
added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. 
To the reaction mixture was added tetrahydroisoquinoline (951 μL, 7.50 mmol, 5.00 equiv.). The resulting 
solution was allowed to stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added 
NaBH4 (57 mg, 2.3 mmol, 1.5 equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine 
in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room 
temperature, stirred for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) 
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and washed with saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was 
extracted with CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and 
filtered. The solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 
1 h to afford crude 149d as a yellow oil. Purification of the crude diamine by silica gel chromatography 
(125 mL silica, 2% NH4OH : 2% MeOH : 96% CHCl3 v/v prepared by extracting saturated NH4OH with 
CHCl3, removing aqueous layer, and adding methanol) afforded pure diamine 149d as a pale yellow oil in 
87% yield (404 mg, 1.30 mmol).  
Rf  = 0.60 (1:9 MeOH/CH2Cl2).  
1H NMR (C6D6, 500 MHz): δ  7.20 (d, J = 8.7 Hz, 2H), 7.01 (dd, J = 5.5, 3.5 Hz, 2H), 6.94 (dd, J = 5.3, 3.6 
Hz, 1H), 6.84 (dd, J = 5.2, 3.7 Hz, 1H), 6.78 (d, J = 8.7 Hz, 2H), 3.69 (d, J = 13.3 Hz, 1H), 3.65 (d, J = 
13.3 Hz, 1H), 3.55 (d, J = 14.7 Hz, 1H), 3.43 (d, J = 14.6 Hz, 1H), 3.31 (s, 3H), 2.91-2.84 (m, 1H), 2.64 (t, 
J = 5.7 Hz, 2H), 2.58 (dd, J = 11.6, 9.0 Hz, 1H), 2.53 (dt, J = 11.1, 5.5 Hz, 1H), 2.43 (dd, J = 11.6, 4.8 Hz, 
1H), 2.29 (dt, J = 11.4, 5.8 Hz, 1H), 1.86-1.85 (br s, 1H), 0.77 (d, J=6.6 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 159.00, 136.06, 135.09, 133.62, 129.36, 127.71, 126.81, 125.96, 125.58, 
113.89, 58.48, 54.65, 53.53, 52.00, 51.21, 45.51, 30.31, 11.15 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C20H27N2O, 311.2123; found, 311.2125. 
 
N-(4-methoxybenzyl)-2-(pyrrolidin-1-yl)propan-1-amine, 149e: 
[(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), imine 147 (259 
μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added pyrrolidine (185 μL, 2.25 mmol, 1.50 equiv.). The resulting solution was allowed to stir 
for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (57 mg, 2.3 mmol, 1.5 
equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added 
dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, stirred 
for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with 
saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 149e as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
3% NH4OH : 3% MeOH : 94% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 149e as a pale yellow oil in 76% yield (282 
mg, 1.14 mmol).  
Rf  = 0.61 (1:9 NH4OH/CHCl3). 
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1H NMR (C6D6, 500 MHz): δ  7.23 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 3.66 (s, 2H), 3.32 (s, 3H), 
2.60-2.54 (m, 2H), 2.49 (dq, J = 11.6, 5.8 Hz, 1H), 2.38-2.35 (m, 4H), 1.72 (br s, 1H), 1.53 (m, 4H), 1.04 
(d, J = 6.4 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 158.99, 133.62, 129.30, 113.85, 57.74, 54.64, 54.01, 53.92, 50.15, 23.80, 
15.53 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O, 249.1967; found, 249.1960. 
 
2-(azetidin-1-yl)-N-(4-methoxybenzyl)propan-1-amine, 149f: 
[(DPEphos)Rh(COD)]BF4 (13 mg, 0.015 mmol, 1.0 mol %), imine 147 (259 
μL, 1.50 mmol, 1.00 equiv.) and dry CH3CN (350 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added azetidine (152 μL, 2.25 mmol, 1.50 equiv.). The resulting solution was allowed to stir 
for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (57 mg, 2.3 mmol, 1.5 
equiv) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added 
dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, stirred 
for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with 
saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 149f as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
4% NH4OH : 4% MeOH : 92% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 149f as a pale yellow oil in 72% yield (253 mg, 
1.08 mmol).  
Rf  = 0.53 (1:9 MeOH/CH2Cl2). 
1H NMR (C6D6, 500 MHz): δ 7.26 – 7.18 (m, 2H), 6.85 – 6.75 (m, 2H), 3.62 (s, 2H), 3.31 (s, 3H), 3.15 – 
2.75 (m, 4H), 2.44 (qd, J = 11.4, 4.7 Hz, 2H), 2.26 – 2.05 (m, 1H), 1.71 (p, J = 6.8 Hz, 2H), 1.30 (s, 1H), 
0.98 (d, J = 6.3 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 159.01, 133.55, 129.28, 113.87, 62.83, 54.62, 54.00, 53.51, 52.19, 17.23, 
15.21 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2O, 235.1810; found, 235.1811. 
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N1-(4-methoxybenzyl)-N2,N2-dimethylpropane-1,2-diamine, 149g: 
[(DPEphos)Rh(COD)]BF4 (15 mg, 0.018 mmol, 5.0 mol %) and imine 147 (70 
mg, 0.40 mmol, 1.00 equiv.) were added to an oven-dried 4 mL vial equipped 
with a stir bar in the glove box. To the reaction mixture was added 
dimethylamine (1 mL, 1 mmol, 2.50 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  
To an oven-dried 25 mL round bottom flask was added NaBH4 (15 mg, 0.6 mmol, 1.5 equiv) and MeOH 
(3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added dropwise, washing the vial 
with MeOH (2.5 mL). The reaction was brought to room temperature, stirred for 2 h, and then concentrated 
in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with saturated NaHCO3 (15 mL). 
The organic layer was separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic 
layers were combined, dried over anhydrous MgSO4 and filtered. The solution was concentrated in vacuo 
followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford crude 149g as a yellow oil. 
Purification of the crude diamine by silica gel chromatography (125 mL silica, 4% NH4OH : 4% MeOH : 
92% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and adding 
methanol) afforded pure diamine 149g as a pale yellow oil in 73% yield (32.5 mg, 0.15 mmol). 
1H NMR (499 MHz, Chloroform-d) δ 7.25 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 3.80 (s, 3H), 3.79 
– 3.69 (m, 2H), 2.85 – 2.73 (m, 1H), 2.55 (dd, J = 11.7, 8.9 Hz, 1H), 2.46 (dd, J = 11.8, 5.0 Hz, 1H), 2.19 
(d, J = 2.8 Hz, 6H), 0.89 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (126 MHz, CDCl3) δ 158.74, 133.04, 129.53, 113.92, 58.42, 55.48, 53.66, 52.52, 40.35, 10.44 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H22N2O, 223.1810; found, 223.1821. 
 
N2-butyl-N1-(4-methoxybenzyl)-N2-methylpropane-1,2-diamine, 149h: 
[(DPEphos)Rh(COD)]BF4 (15 mg, 0.018 mmol, 5.0 mol %), imine 147 (70 
mg, 0.40 mmol, 1.00 equiv.) and dry CH3CN (100 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added methylbutylamine (174 mg, 2 mmol, 5.0 equiv.). The resulting solution was allowed to 
stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (15 mg, 0.6 mmol, 
1.5 equiv) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added 
dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, stirred 
for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with 
saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
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crude 149h as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
4% NH4OH : 4% MeOH : 92% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 149h as a pale yellow oil in 27% yield (28.5 
mg, 0.11 mmol). 
1H NMR (500 MHz, Chloroform-d) δ 7.23 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 3.80 (s, 3H), 3.78 
– 3.65 (m, 2H), 2.94 – 2.82 (m, 1H), 2.53 (dd, J = 11.5, 9.7 Hz, 1H), 2.47 – 2.39 (m, 1H), 2.39 – 2.34 (m, 
1H), 2.25 (ddd, J = 12.4, 8.4, 5.7 Hz, 1H), 2.10 (s, 3H), 1.45 – 1.35 (m, 2H), 1.33 – 1.25 (m, 2H), 0.90 (t, 
J = 7.2 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 129.48, 129.39, 114.02, 110.00, 57.64, 55.47, 53.61, 53.10, 52.68, 36.44, 
30.82, 20.75, 14.21, 10.75. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H28N2O, 265.2280; found, 265.2280. 
 
N2-cyclohexyl-N1-(4-methoxybenzyl)propane-1,2-diamine, 149i: 
[(DPEphos)Rh(COD)]BF4 (15 mg, 0.018 mmol, 5.0 mol %), imine 147 (70 
mg, 0.40 mmol, 1.00 equiv.) and dry CH3CN (100 μL) were added to an 
oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added cyclohexylamine (200 mg, 2.0 mmol, 5.0 equiv.). The resulting solution was 
allowed to stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (15 mg, 
0.6 mmol, 1.5 equiv) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was 
added dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, 
stirred for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed 
with saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 149i as a yellow oil. Purification of the crude diamine by silica gel chromatography (125 mL silica, 
4% NH4OH : 4% MeOH : 92% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 149i as a pale yellow oil in 34% yield (38 mg, 
0.14 mmol). 
1H NMR (499 MHz, Benzene-d6) δ 7.23 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 3.62 (d, J = 1.9 Hz, 
1H), 3.30 (s, 3H), 2.83 – 2.72 (m, 1H), 2.53 – 2.39 (m, 3H), 2.34 (dd, J = 11.3, 7.9 Hz, 1H), 1.85 (d, J = 
12.1 Hz, 2H), 1.74 (d, J = 13.6 Hz, 1H), 1.63 (d, J = 9.6 Hz, 4H), 1.48 (dd, J = 8.5, 3.3 Hz, 3H), 1.24 – 
1.01 (m, 9H), 0.94 (d, J = 6.3 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 158.97, 133.97, 129.24, 113.91, 56.11, 54.68, 53.65, 50.66, 49.58, 
35.25, 33.78, 26.55, 25.00, 19.87 ppm. 
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HRMS (ESI-TOF) m/z: [M+H+] calculated for C17H28N2O, 277.2280; found, 277.2290. 
 
(E)-2-(((2-morpholinopropyl)imino)methyl)phenol, 150: 
[(DPEphos)Rh(COD)]BF4 (9.5 mg, 0.011 mmol, 5.0 mol %), imine (36 mg, 0.22 
mmol, 1.0 equiv.) and dry CH3CN (60 μL) were added to an oven-dried 4 mL vial 
equipped with a stir bar in the glove box. To the reaction mixture was added 
morpholine (98 μL, 1.1 mmol, 5.0 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  This 
mixture was concentrated in vacuo to afford a crude oil. This was run through a short column of basic 
alumina (eluent 90% hexane : 10% ethyl acetate followed by 100% ethyl acetate). The resulting solution 
was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 2 h at 40 °C to afford 
pure imine 150 as a clear yellow oil in 90% yield (50 mg, 0.20 mmol).  In one case where the imine was 
not pure, automated column chromatography was performed to using a 5.5 g cyano column received from 
Teledyne ISCO using hexane as the eluent. 
1H NMR (C6D6, 500 MHz): δ 7.78 (s, 1H), 7.13-7.06 (m, 2H), 6.97 (dd, J = 7.6, 1.6, 1H), 6.72 (td, J = 7.3, 
1.3, 1H), 3.57-3.51 (m, 4H), 3.24 (ddd, J = 12.0, 5.8, 1.1, 1H), 3.01 (ddd, J = 11.9, 7.1, 1.1, 1H), 2.43 
(sextet, J = 6.5, 1H), 2.24-2.17 (m, 4H), 0.78 (d, J = 6.7, 3H), -0.34 (s, 1H) ppm.  
13C NMR (C6D6, 125 MHz): δ 165.7, 162.1, 132.5, 131.4, 119.4, 118.6, 117.6, 67.5, 62.1, 60.0, 49.6, 13.3 
ppm.  
HRMS (EI-TOF) m/z: [M+] calculated for C14H20N2O2, 248.1525; found, 248.1521. 
 
(E)-1-mesityl-N-(2-morpholinopropyl)methanimine, 151: 
[(DPEphos)Rh(COD)]BF4 (8.4 mg, 0.010 mmol, 1.0 mol %), imine (180 mg, 
0.96 mmol, 1.0 equiv.) and dry CH3CN (260 μL) were added to an oven-dried 
4 mL vial equipped with a stir bar in the glove box. To the reaction mixture was 
added morpholine  (430 μL, 5.0 mmol, 5.0 equiv.). The resulting solution was allowed to stir for 24 h at 60 
°C.  This mixture was concentrated in vacuo to afford a crude oil. This was run through a short column of 
basic alumina (eluent 90% hexane : 10% ethyl acetate followed by 100% ethyl acetate). The resulting 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 2 h at 60 °C 
to afford pure imine 151 as a clear yellow oil in 90% yield (237 mg, 0.862 mmol).   
1H NMR (C6D6, 500 MHz): δ 8.43 (s, 1H), 6.74 (s, 2H), 2.79 (sextet, J = 6.2, 1H), 2.43 (s, 6H), 2.38 (t, J = 
4.6, 4H), 2.11 (s, 3H), 1.02 (d, J = 6.7, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 161.0, 138.6, 137.9, 131.6, 129.9, 67.7, 66.0, 60.5, 49.9, 21.21, 21.17, 13.8 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C17H27N2O, 275.2123; found, 275.2120. 
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2-morpholino-N-(4-(trifluoromethyl)benzyl)propan-1-amine, 152: 
[(DPEphos)Rh(COD)]BF4 (5.7 mg, 0.0068 mmol, 1.0 mol %), imine (146 mg, 
0.683 mmol, 1.00 equiv.) and dry CH3CN (180 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added morpholine (296 μL, 3.42 mmol, 5.00 equiv.). The resulting solution was allowed to 
stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (39 mg, 1.0 mmol, 
1.5 equiv.) and MeOH (3 mL) and cooled to 0 °C. The solution of the aminoimine in MeOH was added 
dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room temperature, stirred 
for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) and washed with 
saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer was extracted with 
CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
crude 152 as a yellow oil. Purification of the crude diamine by silica gel chromatography (33 mm × 6 mm 
column, 1% NH4OH : 99% CHCl3 to 1% NH4OH : 1% MeOH : 98% CHCl3 v/v prepared by extracting 
saturated NH4OH with CHCl3, removing aqueous layer, and adding methanol) afforded pure diamine 152 
as a pale yellow oil in a 62% yield (127 mg, 0.420 mmol).  
Rf = 0.50 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 7.40 (d, J = 8.0, 2H), 7.20 (d, J = 7.9, 2H), 3.56-3.47 (m, 6H), 2.52 (dq, J = 
13.2, 6.6, 1H), 2.33 (dd, J = 11.6, 8.6, 1H), 2.24 (dd, J = 11.3, 4.4, 3H), 2.11 (ddd, J = 10.5, 6.5, 3.5, 2H), 
1.85 (s, 1H), 0.72 (d, J = 6.6, 3H) ppm.  
13C NMR (C6D6, 125 MHz): δ 145.99, 129.18 (q, JCF = 32.1), 128.46, 125.40 (q, JCF = 3.8), 125.17 (q, JCF 
= 271.5), 67.55, 59.09, 53.50, 51.92, 48.99, 11.74 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H22N2OF3, 303.1684; found, 303.1670. 
 
4-(((2-morpholinopropyl)amino)methyl)benzoate, 153: 
[(DPEphos)Rh(COD)]BF4 (8.1 mg, 0.0097 mmol, 1.0 mol %), imine (178 
mg, 0.967 mmol, 1.00 equiv.) and dry CH3CN (254 μL) were added to an 
oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added morpholine (418 μL, 4.84 mmol, 5.00 equiv.). The resulting solution was 
allowed to stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (55 mg, 
1.5 mmol, 1.5 equiv) and MeOH (3 mL).  The flask containing the reducing agent was brought to 0 °C and 
the solution of the aminoimine in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). The 
reaction was brought to room temperature, stirred for 2 h, and then concentrated in vacuo. The residue was 
dissolved with CHCl3 (20 mL) and was washed with saturated NaHCO3 (15 mL). The organic layer was 
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separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were combined, 
dried over anhydrous MgSO4 and filtered. The solution was then concentrated in vacuo followed by drying 
under high vacuum (0.05 mm Hg) for 1 h to afford crude 153 as a yellow oil. Purification of the crude 
diamine by silica gel chromatography (33 mm × 6 mm column, 2% NH4OH : 98% CHCl3 to 2% NH4OH : 
2% MeOH : 96% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, 
and adding methanol) afforded pure diamine 153 as a pale yellow oil in 52% yield (132 mg, 0.451 mmol).  
Rf  = 0.67 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 8.14 (d, J = 8.2, 2H), 7.29 (d, J = 8.1, 2H), 3.59 (s, 2H), 3.56-3.47 (m, 7H), 
2.55-2.49 (m, 1H), 2.35 (dd, J = 11.6, 8.5, 1H), 2.23 (ddd, J = 18.7, 8.9, 4.1, 3H), 2.09 (ddd, J = 10.6, 6.5, 
3.5, 2H), 1.92 (s, 1H), 0.71 (d, J = 6.6, 3H) ppm.  
13C NMR (C6D6, 125 MHz): δ 166.7, 147.0, 130.0, 129.5, 128.2, 67.5, 59.1, 53.7, 51.8, 51.6, 48.9, 11.8 
ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H25N2O3, 293.1865; found, 293.1858. 
 
N-(4-bromobenzyl)-2-morpholinopropan-1-amine, 154: 
[(DPEphos)Rh(COD)]BF4 (7.1 mg, 0.0085 mmol, 1.0 mol %), imine (191 mg, 
0.850 mmol, 1.00 equiv.) and dry CH3CN (223 μL) were added to an oven-
dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added morpholine (370 μL, 4.25 mmol, 5.00 equiv.). The resulting solution was allowed to 
stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (48 mg, 1.3 mmol, 
1.5 equiv) and MeOH (3 mL).  The flask containing the reducing agent was brought to 0 °C and the solution 
of the aminoimine in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). The reaction was 
brought to room temperature and stirred for 2 h and then concentrated in vacuo. The residue was dissolved 
with CHCl3 (20 mL) and washed with saturated NaHCO3 (15 mL). The organic layer was separated and the 
aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were combined, dried over 
anhydrous MgSO4 and filtered. The solution was concentrated in vacuo followed by drying under high 
vacuum (0.05 mm Hg) for 1 h to afford crude 154 as a yellow oil. Purification of the crude diamine by silica 
gel chromatography (33 mm × 6 mm column, 3% NH4OH : 97% CHCl3 to 6% NH4OH : 94% CHCl3 v/v 
prepared by extracting saturated NH4OH with CHCl3, and removing aqueous layer) afforded pure diamine 
154 as a clear oil in 76% yield (202 mg, 0.646 mmol).  
Rf  = 0.50 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 7.30 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 8.2 Hz, 2H), 3.52 (ddd, J = 14.9, 6.3, 
3.1 Hz, 4H), 3.46 (s, 2H), 2.50 (ddd, J = 8.6, 6.6, 4.8 Hz, 1H), 2.31 (dd, J = 11.6, 8.5 Hz, 1H), 2.26-2.17 
(m, 3H), 2.07 (ddd, J = 11.2, 6.2, 3.1 Hz, 2H), 1.63 (s, 1H), 0.70 (d, J = 6.6 Hz, 3H) ppm.  
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13C NMR (CDCl3, 125 MHz): δ 139.65, 131.36, 129.72, 120.53, 67.41, 58.66, 53.17, 51.21, 48.39, 11.44 
ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H22BrN2, 313.0916; found, 313.0908. 
 
N,N-dimethyl-4-(((2-morpholinopropyl)amino)methyl)aniline, 155: 
[(DPEphos)Rh(COD)]BF4 (7.2 mg, 0.0086 mmol, 1.0 mol %), imine (160 
mg, 0.850 mmol, 1.00 equiv.) and dry CH3CN (223 μL) were added to an 
oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was then added morpholine (370 μL, 4.25 mmol, 5.00 equiv.). The resulting solution was 
allowed to stir for 24 h at 60 °C.  To an oven-dried 25 mL round bottom flask was added NaBH4 (48 mg, 
1.3 mmol, 1.5 equiv.) and MeOH (3 mL) and cooled to 0 °C.  The aminoimine solution was added dropwise 
to the NaBH4 solution. The vial was washed with MeOH (2.5 mL) and transferred to the flask. The reaction 
was brought to room temperature and stirred for 2 h. The resulting mixture was concentrated in vacuo. The 
residue was dissolved with CHCl3 (20 mL) and washed with saturated NaHCO3 (15 mL). The organic layer 
was separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were 
combined, dried over anhydrous MgSO4, filtered, and concentrated in vacuo followed by drying under high 
vacuum (0.05 mm Hg) for 1 h to afford the crude diamine 155 as a yellow oil. Purification of the crude 
diamine by silica gel chromatography (33 mm × 6 mm column, 3% NH4OH : 97% CHCl3 to 6% NH4OH : 
94% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3 and removing aqueous layer) afforded 
pure diamine 155 as a clear oil in 74% yield (174 mg, 0.629 mmol).  
Rf  = 0.33 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 7.34 (d, J = 8.6 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 3.79 (d, J = 12.9 Hz, 1H), 
3.74 (d, J = 13.0 Hz, 1H), 3.53 (dtd, J = 13.9, 10.8, 5.4 Hz, 4H), 2.66-2.55 (m, 1H), 2.54-2.50 (m, 1H), 2.53 
(s, 6H), 2.42 (dd, J = 11.5, 4.8 Hz, 1H), 2.29-2.21 (m, 2H), 2.15-2.07 (m, 2H), 1.80 (s, 1H), 0.75 (d, J = 6.6 
Hz, 3H) ppm.  
13C NMR (CDCl3, 125 MHz): δ 149.70, 128.96, 128.61, 112.61, 67.45, 58.62, 53.27, 51.03, 48.32, 40.75, 
11.41 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H28N3O, 278.2232; found, 278.2234. 
 
N-(2-chlorobenzyl)-2-morpholinopropan-1-amine, 156: 
[(DPEphos)Rh(COD)]BF4 (36 mg, 0.043 mmol, 5.0 mol %), imine (153 mg, 0.85 
mmol, 1.00 equiv.) and dry CH3CN (254 μL) were added to an oven-dried 4 mL 
vial equipped with a stir bar in the glove box. To the reaction mixture was added 
morpholine (368 μL, 4.3 mmol, 5.00 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  
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To an oven-dried 25 mL round bottom flask was added NaBH4 (55 mg, 1.5 mmol, 1.5 equiv) and MeOH 
(3 mL).  The flask containing the reducing agent was brought to 0 °C and the solution of the aminoimine 
in MeOH was added dropwise, washing the vial with MeOH (2.5 mL). The reaction was brought to room 
temperature, stirred for 2 h, and then concentrated in vacuo. The residue was dissolved with CHCl3 (20 mL) 
and was washed with saturated NaHCO3 (15 mL). The organic layer was separated and the aqueous layer 
was extracted with CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous MgSO4 
and filtered. The solution was then concentrated in vacuo followed by drying under high vacuum (0.05 mm 
Hg) for 1 h to afford crude 156 as a yellow oil. Purification of the crude diamine by silica gel 
chromatography (33 mm × 6 mm column, 2% NH4OH : 98% CHCl3 to 2% NH4OH : 2% MeOH : 96% 
CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and adding 
methanol) afforded pure diamine 156 as a pale yellow oil in 44% yield (132 mg, 0.451 mmol).  
Rf = 0.63 (1:9 NH4OH/CHCl3) 
1H NMR (C6D6, 500 MHz): δ 7.35 (dd, J = 7.6, 1.6, 1H), 7.19 (dd, J = 7.9, 1.2, 1H), 6.93 (td, J = 7.5, 1.2, 
1H), 6.80 (td, J = 7.7, 1.7, 1H), 3.87 (d, J = 14.3, 1H), 3.79 (d, J = 14.4, 1H), 3.58-3.50 (m, 4H), 2.55 (dqd, 
J = 8.7, 6.6, 4.7, 1H), 2.39 (dd, J = 11.6, 8.7, 1H), 2.31 (dd, J = 11.6, 4.7, 1H), 2.22-2.18 (m, 2H), 2.06 (ddd, 
J = 10.6, 6.3, 3.8, 2H), 2.00 (s, 1H), 0.70 (d, J = 6.6, 3H) ppm.  
13C NMR (C6D6, 125 MHz): δ 138.0, 133.9, 130.5, 129.6, 128.4, 126.8, 67.5, 58.7, 51.6, 51.2, 48.4, 11.5 
ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calcd for C14H22N2OCl, 269.1421; found, 269.1416. 
 
N-benzhydryl-2-morpholinopropan-1-amine, 158: [(DPEphos)Rh(COD)]BF4 
(42 mg, 0.050 mmol, 5.0 mol %), imine (221 mg, 1.00 mmol, 1.00 equiv.) and dry 
CH3CN (350 μL) were added to an oven-dried 4 mL vial equipped with a stir bar 
in the glove box. To the reaction mixture was added morpholine (216 μL, 2.50 
mmol, 2.50 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  
To an oven-dried 25 mL Schlenk flask under N2 was added LiAlH4 (76 mg, 2.0 mmol, 2.0 equiv) and THF 
(5 mL) and cooled to 0 °C. The solution of the aminoimine in THF was added dropwise, via syringe through 
septa. The reaction was brought to room temperature, stirred for 2 h, and then quenched with 1 M NaOH 
(5 mL). The residue was dissolved with CHCl3 (20 mL) and washed with 1 M NaOH (15 mL). The organic 
layer was separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were 
combined, dried over anhydrous MgSO4 and filtered. The solution was concentrated in vacuo followed by 
drying under high vacuum (0.05 mm Hg) for 1 h to afford crude 158 as a yellow oil. Purification of the 
crude diamine by silica gel chromatography (125 mL silica, 1% NH4OH : 99% CHCl3 v/v prepared by 
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extracting saturated NH4OH with CHCl3 and removing aqueous layer) afforded pure diamine 158 as a pale 
yellow oil in 40% yield (137 mg, 0.600 mmol).  
Rf  = 0.70 (1:9 MeOH/CH2Cl2).   
1H NMR (C6D6, 500 MHz): δ 7.51 (d, J = 7.0 Hz, 2H), 7.39 (d, J = 7.2 Hz, 2H), 7.16 (t, J = 7.7 Hz, 2H), 
7.13 – 7.10 (m, 2H), 7.03 (dt, J = 14.8, 7.3 Hz, 2H), 4.72 (s, 1H), 3.44 (dddd, J = 19.9, 10.5, 6.9, 3.1 Hz, 
4H), 2.56 (h, J = 6.7 Hz, 1H), 2.41 (d, J = 6.7 Hz, 2H), 2.17 (ddd, J = 10.3, 4.8, 2.0 Hz, 2H), 2.03 (ddd, J 
= 11.3, 6.1, 3.2 Hz, 2H), 1.33 (br s, 1H), 0.65 (d, J = 6.6 Hz, 3H) ppm.   
13C NMR (CDCl3, 125 MHz): δ 144.64, 144.33, 128.71, 128.64, 127.59 (2C, coincident peaks), 127.22, 
127.12, 67.71, 67.69, 59.00, 50.87, 48.66, 11.85 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C20H27N2O, 311.2123; found, 311.2123. 
 
N-(2-morpholinopropyl)cyclohexanamine, 159: [(DPEphos)Rh(COD)]BF4 (13 
mg, 0.015 mmol, 1.0 mol %), imine (259 μL, 1.50 mmol, 1.00 equiv.) and dry 
CH3CN (350 μL) were added to an oven-dried 4 mL vial equipped with a stir bar in 
the glove box. To the reaction mixture was added morpholine (194 μL, 2.25 mmol, 
1.50 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  To an oven-dried 25 mL Schlenk 
flask was added LiAlH4 (114 mg, 3.00 mmol, 2.00 equiv.) and THF (5 mL) and cooled to 0 °C. The solution 
of the aminoimine in THF was added dropwise, via syringe through septa. The reaction was brought to 
room temperature, stirred for 2 h, and then quenched with 5 mL 1 M NaOH. The residue was dissolved 
with CHCl3 (20 mL) and washed with 1 M NaOH (15 mL). The organic layer was separated and the aqueous 
layer was extracted with CHCl3 (15 mL × 3). All organic layers were combined, dried over anhydrous 
MgSO4 and filtered. The solution was concentrated in vacuo followed by drying under high vacuum (0.05 
mm Hg) for 1 h to afford crude 159 as a yellow oil. Purification of the crude diamine by silica gel 
chromatography (125 mL silica, 1% saturated NH4OH : 98% CHCl3 v/v prepared by extracting saturated 
NH4OH with CHCl3 and then removing aqueous layer) afforded pure diamine 159 as a pale yellow oil in 
44% yield (137 mg, 0.600 mmol).  
Rf  = 0.37 (1:9 MeOH/CH2Cl2).   
1H NMR (C6D6, 400 MHz): δ 3.51 (dddd, J = 13.9, 10.8, 7.0, 3.9 Hz, 4H), 2.52 (h, J = 6.6 Hz, 1H), 2.39 
(d, J = 6.6 Hz, 2H), 2.33 – 2.20 (m, 2H), 2.08 (dddd, J = 9.6, 6.1, 3.6, 1.0 Hz, 2H), 1.86 – 1.69 (m, 3H), 
1.63 (dq, J = 11.3, 4.2 Hz, 2H), 1.48 (dd, J = 11.9, 4.5 Hz, 1H), 1.31 – 0.95 (m, 5H), 0.73 (d, J = 6.5 Hz, 
3H) ppm.   
13C NMR (C6D6, 125 MHz): δ 171.66, 137.48, 114.00, 52.78, 39.94, 28.54, 27.82, 26.95, 26.14 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H27N2O, 227.2123; found 227.2122. 
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(E)-1-(4-methoxyphenyl)-N-(2-methyl-2-morpholinopropyl) 
methanimine, 160: [(DPEphos)Rh(COD)]BF4 (12 mg, 0.015 mmol, 5.0 mol 
%), imine (54.5 mg, 0.288 mmol, 1.00 equiv.) and dry CH3CN (77 μL) were 
added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. 
To the reaction mixture was added morpholine (126 μL, 1.46 mmol, 5.00 equiv.). The resulting solution 
was allowed to stir for 24 h at 60 °C.  To an oven-dried 10 mL round bottom flask was added NaBH4 (17 
mg, 0.44 mmol, 1.5 equiv.) and MeOH (0.5 mL).  The flask containing the reducing agent was brought to 
0 °C and the solution of the aminoimine in MeOH was added dropwise, washing the vial with MeOH (0.5 
mL). The reaction was brought to room temperature, stirred for 2 h, and then concentrated in vacuo. The 
residue was dissolved with CHCl3 (10 mL) and was washed with saturated NaHCO3 (10 mL). The organic 
layer was separated and the aqueous layer was extracted with CHCl3 (15 mL × 3). All organic layers were 
combined, dried over anhydrous MgSO4 and filtered. The solution was then concentrated in vacuo followed 
by drying under high vacuum (0.05 mm Hg) for 1 h to afford crude 160 as a yellow oil. Purification of the 
crude diamine by silica gel chromatography (33 mm × 6 mm column, 2% NH4OH : 98% CHCl3 to 2% 
NH4OH : 2% MeOH : 96% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded pure diamine 160 as a clear oil in 58% yield (46 mg, 0.17 
mmol).  
Rf  = 0.53 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 7.25 (d, J = 8.6, 2H), 6.82 (d, J = 8.6, 2H), 3.67 (s, 2H), 3.54 (t, J = 4.6, 4H), 
3.33 (s, 3H), 2.35 (s, 2H), 2.19 (t, J = 4.6, 4H), 0.90 (s, 6H) ppm.  
13C NMR (CDCl3, 125 MHz): δ 159.1, 133.4, 129.4, 113.9, 67.8, 56.7, 56.0, 54.6, 53.7, 45.9, 21.7 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H27N2O2, 279.2073; found, 279.2075. 
 
1-phenyl-2-(pyrrolidin-1-yl)propan-1-amine, 163a: [(DPEphos)Rh(COD)]BF4 (3.4 
mg, 0.0040 mmol, 2.0 mol %), imine (50 mg, 0.20 mmol, 1.0 equiv.) and dry CH3CN (53 
μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To 
the reaction mixture was then added pyrrolidine (17 μL, 0.20 mmol, 1.0 equiv.). The 
resulting solution was allowed to stir for 24 h at 60 °C.  The solution was concentrated in vacuo followed 
by the addition of 10% aqueous HCl (2 mL). The vial was capped and stirred at 60 °C for 2 h. The solution 
was transferred to a separatory funnel. The reaction vial was rinsed with 10% aqueous HCl (1 mL) followed 
by CHCl3 (4 mL). The aqueous layer was washed with CHCl3 (10 mL  3) and was then basified using 
KOH pellets until a pH ~12 was obtained. The aqueous layer was extracted with CHCl3 (50 mL  3). All 
organic layers were then combined, dried over anhydrous MgSO4 and filtered. The solution was 
concentrated in vacuo followed by drying under high vacuum (10 mm Hg) for 0.5 h to afford the crude 
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diamine 163a as yellow oil. Purification of the crude diamine by automated silica gel chromatography (4 
g, MeOH : 1% NH4OH / CHCl3 = 0 : 100 to 5 : 95  as gradient afforded pure diamine 163a as a yellow oil 
in 50% yield (20 mg, 0.10 mmol).  
Rf  = 0.17 (1:9 MeOH/CH2Cl2). 
1H NMR (CDCl3, 500 MHz):  δ 7.37 (d, J = 7.2 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 
4.39 (d, J = 3.1 Hz, 1H), 2.72 – 2.61 (m, 4H), 2.38 (qd, J = 6.5, 3.1 Hz, 1H), 1.85 – 1.78 (m, 4H), 1.69 (s, 
2H), 0.85 (d, J = 6.5 Hz, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 143.79, 128.00, 126.80, 126.44, 66.22, 56.44, 52.32, 23.47, 11.78 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H21N2, 205.1705; found, 205.1702. 
 
2-morpholino-1-phenylpropan-1-amine, 163b: [(DPEphos)Rh(COD)]BF4 (3.0 mg, 
0.0036 mmol, 1.0 mol %), imine (100 mg, 0.36 mmol, 1.0 equiv.) and dry CH3CN (95 
μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To 
the reaction mixture was added morpholine (155 μL, 1.79 mmol, 5.0 equiv.). The 
resulting solution was allowed to stir for 24 h at 60 °C.  The solution was then concentrated in vacuo 
followed by the addition of 10% aqueous HCl (2 mL) while stirring at room temperature. This was capped 
and heated to 60 °C for 2 h. The solution was then transferred to a separatory funnel. The reaction vial was 
washed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). The aqueous layer was washed with 
CHCl3 (10 mL  3) and was then basified using KOH pellets until a pH ~12 was obtained. The aqueous 
layer was washed with CHCl3 (50 mL  3). All organic layers were then combined, dried over anhydrous 
MgSO4 and filtered. The solution was concentrated in vacuo followed by drying under high vacuum (0.05 
mm Hg) for 1 h to afford the crude diamine 163b as yellow oil. Purification of the crude diamine by 
automated silica gel chromatography (4 g, MeOH : 1% NH4OH / CHCl3 = 0 : 100 to 10 : 90 as gradient) 
afforded pure diamine 163b as a clear oil in 79% yield (61 mg, 0.28 mmol).  
Rf  = 0.48 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ 7.32 (d, J = 7.4, 2H), 7.23 (t, J = 7.6, 2H), 7.13 (t, J = 7.3, 1H), 3.94 (d, J = 
4.4, 1H), 3.52 (t, J = 4.4, 4H), 2.30-2.26 (m, 1H), 2.23 (t, J = 4.5, 4H), 1.34 (s, 2H), 0.78 (d, J = 6.7, 3H) 
ppm.  
13C NMR (C6D6, 125 MHz): δ 165.7, 162.1, 132.5, 131.4, 119.4, 118.6, 117.6, 67.5, 62.1, 60.0, 49.6, 13.3 
ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H21N2O, 221.1654; found, 221.1651. 
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(1R,2S)-N2,N2-dimethyl-1-phenylpropane-1,2-diamine, 163c: 
[(DPEphos)Rh(COD)]BF4 (15.0 mg, 0.018 mmol, 5.0 mol %) and imine (100 mg, 0.36 
mmol, 1.0 equiv.) were added to an oven-dried 4 mL vial equipped with a stir bar in the 
glove box. To the reaction mixture was added dimethylamine solution (1 mL, 1.0 mmol, 2.5 
equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  The solution was then concentrated in 
vacuo followed by the addition of 10% aqueous HCl (2 mL) while stirring at room temperature. This was 
capped and heated to 60 °C for 2 h. The solution was then transferred to a separatory funnel. The reaction 
vial was washed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). The aqueous layer was washed 
with CHCl3 (10 mL  3) and was then basified using KOH pellets until a pH ~12 was obtained. The aqueous 
layer was washed with CHCl3 (50 mL  3). All organic layers were then combined, dried over anhydrous 
MgSO4 and filtered. The solution was concentrated in vacuo followed by drying under high vacuum (0.05 
mm Hg) for 1 h to afford the crude diamine 163c as yellow oil. Purification of the crude diamine by 
automated silica gel chromatography (4 g, MeOH : 1% NH4OH / CHCl3 = 0 : 100 to 10 : 90 as gradient) 
afforded pure diamine 163c as a clear oil in 22% yield (15.6 mg, 0.088 mmol).  
 
(1R,2S)-N2-cyclohexyl-1-phenylpropane-1,2-diamine, 163d: 
[(DPEphos)Rh(COD)]BF4 (15.0 mg, 0.018 mmol, 5.0 mol %), imine (100 mg, 0.36 
mmol, 1.0 equiv.) and dry CH3CN (95 μL) were added to an oven-dried 4 mL vial 
equipped with a stir bar in the glove box. To the reaction mixture was added 
cyclohexylamine (200 μL, 2 mmol, 5.0 equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  
The solution was then concentrated in vacuo followed by the addition of 10% aqueous HCl (2 mL) while 
stirring at room temperature. This was capped and heated to 60 °C for 2 h. The solution was then transferred 
to a separatory funnel. The reaction vial was washed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 
mL). The aqueous layer was washed with CHCl3 (10 mL  3) and was then basified using KOH pellets 
until a pH ~12 was obtained. The aqueous layer was washed with CHCl3 (50 mL  3). All organic layers 
were then combined, dried over anhydrous MgSO4 and filtered. The solution was concentrated in vacuo 
followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford the crude diamine 163d as yellow 
oil. Purification of the crude diamine by automated silica gel chromatography (4 g, MeOH : 1% NH4OH / 
CHCl3 = 0 : 100 to 10 : 90 as gradient) afforded pure diamine 163d as a clear oil in 45% yield (41.5 mg, 
0.18 mmol).  
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4-morpholino-1-phenylpentan-3-amine, 164: [(DPEphos)Rh(COD)]BF4 (8 mg, 0.01 
mmol, 1 mol %), imine (267 μL, 1.00 mmol, 1.00 equiv.) and dry CH3CN (300 μL) were 
added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the reaction 
mixture was added morpholine (431 μL, 5.00 mmol, 5.00 equiv.). The resulting solution 
was allowed to stir for 24 h at 60 °C.  The solvent was reduced under reduced pressure.  3 M HCl (5 mL) 
was then added to the scintillation and the diphasic solution was vigorously stirred for 18 hours.  The 
organic layer was discarded and the aqueous layer was basified with 5 M NaOH until a pH ~12 was 
obtained.  The aqueous layer was extracted with CHCl3 (75 mL  3).  The organic extracts were combined, 
dried over anhydrous MgSO4, and filtered. The solution was concentrated in vacuo followed by drying 
under high vacuum (0.05 mm Hg) for 1 h to afford crude diamine 164 as yellow oil. Purification of the 
crude diamine by silica gel chromatography (125 mL silica, 2% MeOH : 2% NH4OH: 96% CHCl3 v/v 
prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and adding methanol) 
afforded pure diamine 164 as a pale yellow oil in 73% yield (119 mg, 0.731 mmol).  
Rf  = 0.40 (1:9 MeOH/CH2Cl2).   
1H NMR (C6D6, 500 MHz): δ 7.19 – 7.14 (m, 3H), 7.09 – 7.03 (m, 2H), 3.57 – 3.46 (m, 4H), 2.72 (ddd, J 
= 13.6, 9.8, 5.2 Hz, 1H), 2.57 – 2.47 (m, 2H), 2.14 (tq, J = 10.8, 6.1, 4.9 Hz, 4H), 1.86 (p, J = 6.5 Hz, 
1H), 1.79 (dddd, J = 13.3, 10.1, 7.0, 3.3 Hz, 1H), 1.40 (dddd, J = 13.8, 9.7, 8.7, 5.2 Hz, 1H), 0.72 (d, J = 
6.6 Hz, 5H) ppm.   
13C NMR (C6D6, 125 MHz): δ 142.65, 128.60, 128.59, 126.00, 67.70, 64.20, 51.77, 50.60, 37.04, 33.17, 
9.73 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O, 249.1967; found, 249.1963. 
 
2-morpholino-1-(p-tolyl)propan-1-amine, 165: [(DPEphos)Rh(COD)]BF4 (5.5 mg, 
0.0066 mmol, 2.0 mol %), imine (82 mg, 0.33 mmol, 1.0 equiv.) and dry CH3CN (87 μL) 
were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added morpholine (140 μL, 1.6 mmol, 5.0 equiv.). The resulting 
solution was allowed to stir for 24 h at 60 °C.  The solution was then concentrated in vacuo followed by 
the addition of 10% aqueous HCl (2 mL) while stirring at room temperature. This was capped and heated 
to 60 °C for 2 h. The solution was then transferred to a separatory funnel. The reaction vial was washed 
with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). The aqueous layer was washed with CHCl3 (10 
mL  3) and was then basified using KOH pellets until a pH ~12 was obtained. The aqueous layer was 
washed with CHCl3 (50 mL  3). All organic layers were then combined, dried over anhydrous MgSO4 and 
filtered. The solution was then concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) 
for 1 h to afford the crude diamine 165 as yellow oil. Purification of the crude diamine by automated silica 
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gel chromatography (4 g, MeOH : 1% NH4OH / CHCl3 = 0 : 100 to 18 : 82  as gradient) afforded pure 
diamine 165 as a clear oil in 67% yield (52 mg, 0.22 mmol). 
Rf  = 0.40 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500MHz): δ 7.27 (d, J = 8.0, 2H), 7.08 (d, J = 7.8, 2H), 3.96 (d, J = 4.3, 1H), 3.54 (dd, J 
= 5.0, 2.9, 4H), 2.30 (qd, J = 6.7, 4.4, 1H), 2.25 (t, J = 4.6, 4H), 2.19 (s, 3H), 1.22 (s, 2H), 0.82 (d, J = 6.7, 
3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 142.3, 136.0, 129.0, 127.4, 67.6, 66.0, 55.6, 51.3, 21.1, 10.1 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2O, 235.1810; found, 235.1812. 
 
1-(4-methoxyphenyl)-2-morpholinopropan-1-amine, 166: [(DPEphos)Rh(COD)]BF4 
(4.5 mg, 0.0054 mmol, 2.0 mol %), imine (77 mg, 0.27 mmol, 1.0 equiv.) and dry CH3CN 
(72 μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. 
To the reaction mixture was added morpholine (120 μL, 1.4 mmol, 5.0 equiv.). The 
resulting solution was allowed to stir for 24 h at 60 °C.  The solution was then concentrated in vacuo 
followed by the addition of 10% aqueous HCl (2 mL) while stirring at room temperature. This was capped 
and heated to 60 °C for 2 h. The solution was then transferred to a separatory funnel. The reaction vial was 
washed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). The aqueous layer was washed with 
CHCl3 (10 mL  3) and was basified using KOH pellets until a pH ~12 was obtained. The aqueous layer 
was washed with CHCl3 (50 mL  3). All organic layers were combined, dried over anhydrous MgSO4 and 
filtered. The solution was then concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) 
for 1 h to afford the crude diamine 166 as yellow oil. Purification of the crude diamine by automated silica 
gel chromatography (24 g, MeOH : 1% NH4OH / CHCl3 = 0 : 100 to 10 : 90 as gradient) afforded pure 
diamine 166 as a clear oil in 80% yield (54 mg, 0.22 mmol).  
Rf  = 0.48 (1:9 NH4OH/CHCl3).  
1H NMR (C6D6, 500 MHz): δ 7.26 (d, J = 8.3, 2H), 6.88 (d, J = 8.7, 2H), 3.94 (d, J = 4.4, 1H), 3.54 (t, J = 
4.5, 4H), 3.37 (s, 3H), 2.30-2.25 (m, 5H), 1.19 (s, 2H), 0.83 (d, J = 6.7, 3H) ppm.  
13C NMR (C6D6, 125 MHz): δ 128.34, 159.03, 137.3, 113.8, 67.6, 66.0, 55.4, 54.8, 51.3, 10.1 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2O2, 251.1760; found, 251.1759. 
 
2-morpholino-1-(naphthalen-1-yl)propan-1-amine, 167: 
[(DPEphos)Rh(COD)]BF4 (3.4 mg, 0.0040 mmol, 2.0 mol %), imine (60 mg, 0.20 
mmol, 1.0 equiv.) and dry CH3CN (53 μL) were added to an oven-dried 4 mL vial 
equipped with a stir bar in the glove box. To the reaction mixture was then added 
morpholine (88 μL, 1.0 mmol, 5.0 equiv.). The resulting solution was allowed to stir 
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for 24 h at 60 °C.  The solution was then concentrated in vacuo followed by the addition of 10% aqueous 
HCl (2 mL). The vial was capped and stirred at 60 °C for 2 h. The solution was then transferred to a 
separatory funnel. The reaction vial was rinsed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). 
The aqueous layer was washed with CHCl3 (10 mL × 3) and was then basified using KOH pellets until a 
pH ~12 was obtained. The aqueous layer was extracted with CHCl3 (50 mL  3). All organic layers were 
then combined, dried over anhydrous MgSO4 and filtered. The solution was concentrated in vacuo followed 
by drying under high vacuum (10 mm Hg) for 0.5 h to afford the pure diamine 167 as an off white solid in 
78% yield (42 mg, 0.16 mmol).  
m.p. 103–105 °C. 
1H NMR (C6D6, 500 MHz): δ 8.06 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 7.2 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 
7.62 (d, J = 8.1 Hz, 1H), 7.39 (ddd, J = 8.7, 7.0, 1.7 Hz, 2H), 7.30 (ddd, J = 8.0, 6.8, 1.1 Hz, 1H), 4.93 (d, 
J = 3.5 Hz, 1H), 3.54 (q, J = 4.2 Hz, 4H), 2.60 (qd, J = 6.6, 3.5 Hz, 1H), 2.34 (t, J = 4.5 Hz, 4H), 1.17 (s, 
2H), 0.77 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (CDCl3, 125 MHz) δ 141.21, 135.12, 132.33, 130.07, 128.11, 126.40, 126.35, 126.03, 125.73, 
124.01, 68.17, 64.20, 51.95, 51.87, 10.84 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C17H23N2O, 271.1810; found, 270.1803. 
 
1-(4-bromophenyl)-2-morpholinopropan-1-amine, 168: [(DPEphos)Rh(COD)]BF4 
(2.5 mg, 0.0030 mmol, 1.0 mol %), imine (100 mg, 0.30 mmol, 1.0 equiv.) and dry 
CH3CN (80 μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the 
glove box. To the reaction mixture was then added morpholine (79 μL, 0.90 mmol, 3.0 
equiv.). The resulting solution was allowed to stir for 24 h at 60 °C.  The solution was 
then concentrated in vacuo followed by the addition of 10% aqueous HCl (3 mL). The vial was then capped 
and stirred at 60 °C for 2 h. The solution was then transferred to a separatory funnel. The reaction vial was 
rinsed with 10% aqueous HCl (1 mL) followed by CHCl3 (4 mL). The aqueous layer was washed with 
CHCl3 (10 mL × 3) and was then basified using KOH pellets until a pH ~12 was obtained. The aqueous 
layer was extracted with CHCl3 (50 mL  3). All organic layers were then combined, dried over anhydrous 
MgSO4 and filtered. The solution was concentrated in vacuo followed by drying under high vacuum (10 
mm Hg) for 0.5 h to afford the pure diamine 168 as an off white solid in 69% yield (62 mg, 0.21 mmol).  
m.p. 63–65 °C. 
1H NMR (C6D6, 500 MHz): δ 7.33 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 8.3 Hz, 2H), 3.69 (d, J = 4.6 Hz, 1H), 
3.48 (t, J = 5.0 Hz, 4H), 2.15 (td, J = 4.2, 1.9 Hz, 4H), 2.09 (qd, J = 6.7, 4.6 Hz, 1H), 0.95 (s, 2H), 0.67 (d, 
J = 6.7 Hz, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 144.96, 131.86, 129.75, 121.09, 68.03, 66.20, 56.00, 51.64, 10.53 ppm.  
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HRMS (ESI-TOF) m/z: [M+H+] calcd for C13H20N2OBr, 299.0759; found, 299.0761. 
 
1-cyclohexyl-2-morpholinopropan-1-amine, 169: [(DPEphos)Rh(COD)]BF4 (8 mg, 
0.01 mmol, 1 mol %), imine (257 mg, 1.00 mmol, 1.00 equiv.) and dry CH3CN (300 μL) 
were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added morpholine (604 μL, 7.00 mmol, 7.00 equiv.). The resulting 
solution was allowed to stir for 24 h at 60 °C.  Subjection of the crude aminoimine to 
silica gel chromatography (125 mL silica, 1% MeOH : 1% NH4OH : 98% CHCl3 to 2% MeOH : 2% NH4OH 
: 96% CHCl3 gradient v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, 
and adding methanol) afforded 1,2-diamine 169 as a pale yellow oil in 58% yield (141 mg, 1.08 mmol). 
Rf  = 0.53 (1:9 MeOH/CH2Cl2).   
1H NMR (C6D6, 500 MHz): δ 3.67 – 3.43 (m, 4H), 2.35 (t, J = 5.8 Hz, 1H), 2.20 (tq, J = 11.4, 6.4, 5.4 Hz, 
4H), 2.07 (p, J = 6.5 Hz, 1H), 1.69 (td, J = 25.1, 23.3, 13.1 Hz, 4H), 1.42 (d, J = 9.0 Hz, 2H), 1.29 – 1.05 
(m, 3H), 1.01 – 0.84 (m, 2H), 0.82 (d, J = 6.6 Hz, 5H) ppm.   
13C NMR (C6D6, 125 MHz): δ 67.49, 61.10, 56.73, 50.30, 40.43, 30.27, 28.24, 27.03, 26.86, 26.70, 9.60 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H27N2O, 227.2123; found, 227.2121. 
 
3.3. Experimental Procedures of Chapters 2.2.3 and 2.2.4 
General Secondary Allyl Amine Hydroamination Procedure A: 
 
[Rh(COD)2BF4] (10 mg, 0.025 mmol, 5.0 mol %), dppb (11 mg, 0.025 mmol, 5.0 mol %), allyl amine 
(0.50 mmol, 1.00 equiv.), amine nucleophile (2.5 mmol, 5.0 equiv., freshly distilled) and dry DME (144 
μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. The resulting 
solution was allowed to stir for 24 h at 60 °C. After 24 h, the solution was concentrated in vacuo followed 
by drying under high vacuum (0.05 mm Hg) for 1 h to afford crude 1,2-diamine as a yellow oil. 
Purification of the crude diamine by silica gel chromatography (75 mL silica, 3% NH4OH : 3% MeOH : 
94% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and 
adding methanol) afforded pure diamine. 
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N-(4-methoxyphenyl)prop-2-en-1-amine, 170: The imine (2.6 mL, 15 mmol, 1.0 equiv.) was added to a 
250 mL round bottom flask (precooled at 0 °C) containing MeOH (50 mL). The resulting solution was 
stirred for 10 min followed by the portion-wise addition of NaBH4 (851.2 mg, 22.5 mmol, 1.5 equiv.) at 0 
°C. It was then stirred overnight at room temperature and then concentrated in vacuo. The residue was 
dissolved with CHCl3 (50 mL) and was washed with saturated NaHCO3 (100 mL). The organic layer was 
separated and the aqueous layer was extracted with CHCl3 (50 mL × 3). All organic layers were combined, 
dried over anhydrous MgSO4 and filtered. The solution was then concentrated in vacuo followed by drying 
under high vacuum (1 mm Hg) for 15 min to afford crude 170 as a yellow oil. Purification of the crude 
amine by distillation afforded pure amine 170 as a clear oil in 90% yield (2.39 g, 13.5 mmol). 
1H NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 1H), 5.93 (ddt, J = 17.2, 10.2, 
6.0 Hz, 1H), 5.19 (dq, J = 17.2, 1.7 Hz, 1H), 5.10 (dq, J = 10.3, 1.5 Hz, 1H), 3.78 (s, 3H), 3.72 (s, 2H), 3.26 
(dt, J = 5.9, 1.5 Hz, 2H), 1.25 (s, 1H) ppm.   
13C NMR (CDCl3, 125 MHz): δ 158.46, 136.76, 132.31, 129.20, 115.74, 113.60, 55.08, 52.55, 51.58 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C11H16NO, 178.1232; found: 178.1230.  
 
 N-(4-bromophenyl)prop-2-en-1-amine:  Amine was prepared according to the 
published literature procedure.326 
 
N-(thiophen-2-ylmethyl)prop-2-en-1-amine: Amine was prepared according to the 
synthesis of 170. 
1H NMR (400 MHz, Benzene-d6) δ 6.88 (dt, J = 5.1, 1.2 Hz, 1H), 6.79 – 6.68 (m, 2H), 5.74 (ddtd, J = 
17.1, 10.2, 5.9, 1.0 Hz, 1H), 5.06 (ddt, J = 17.2, 2.8, 1.2 Hz, 1H), 4.97 (ddq, J = 10.1, 2.4, 1.3 Hz, 1H), 
3.65 (s, 3H), 2.99 (d, J = 5.9 Hz, 2H) ppm. 
13C NMR (126 MHz, Benzene-d6) δ 145.25, 137.35, 126.64, 124.63, 124.46, 115.59, 51.64, 47.97 ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C8H12NS 153.0612; found 153.0611. 
 
N-allyl-3,7-dimethylocta-2,6-dien-1-amine, 3aa. Amine was prepared 
according to the synthesis of 170 and is reported as a mixture of diastereomers. 
Rf  = 0.24 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz) 1H NMR (500 MHz, Benzene-d6) δ 5.88 (ddtd, J = 17.0, 10.3, 5.8, 2.9 Hz, 
1H), 5.37 – 5.29 (m, 1H), 5.16 (dddt, J = 14.6, 5.9, 3.9, 1.7 Hz, 2H), 5.01 (dq, J = 10.2, 1.6 Hz, 1H), 3.19 
85 
 
– 3.14 (m, 2H), 3.12 (tt, J = 5.7, 1.5 Hz, 2H), 2.13 (q, J = 7.1 Hz, 1H), 2.09 – 2.00 (m, 3H), 1.68 – 1.62 
(m, 5H), 1.54 (d, J = 6.0 Hz, 5H) ppm. 
13C NMR (C6D6, 125 MHz): 13C NMR (126 MHz, Benzene) δ 138.23, 138.20, 137.15, 136.93, 131.57, 
131.28, 125.29, 124.81, 124.73, 124.41, 115.06, 52.38, 52.23, 47.04, 46.95, 40.11, 32.49, 27.12, 27.03, 
25.90, 23.58, 17.78, 17.72, 16.34 ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C13H24N 194.1909; found 194.1913. 
 
N-allylcyclohexanamine:  Amine was prepared according to the synthesis of 170. 
1H NMR (C6D6, 500 MHz) 1H NMR (500 MHz, Benzene-d6) δ 5.91 (ddtd, J = 16.0, 10.3, 
5.8, 1.0 Hz, 1H), 5.18 (dt, J = 17.2, 1.4 Hz, 1H), 5.05 – 4.98 (m, 1H), 3.21 – 3.10 (m, 2H), 
2.32 (ddd, J = 13.4, 9.8, 3.5 Hz, 1H), 1.74 (d, J = 10.3 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.52 – 1.46 (m, 1H), 
1.14 (dq, J = 19.9, 11.4 Hz, 4H), 1.01 (q, J = 9.5, 8.9 Hz, 2H), 0.53 (s, 1H) ppm. 
13C NMR (C6D6, 125 MHz): 13C NMR (126 MHz, Benzene) δ 138.72, 114.67, 56.27, 49.91, 33.98, 26.71, 
25.25 ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C9H18N 140.1439; found 140.1436. 
 
N-(4-methoxybenzyl)-2-morpholinopropan-1-amine, 149a:  The general 
secondary allyl amine hydroamination procedure A was followed using allyl 
amine 170 (89 mg, 0.50 mmol, 1.00 equiv.) and morpholine (219 μL, 2.5 
mmol, 5.0 equiv., freshly distilled). Diamine 149a was isolated as a pale 
yellow oil in 70% yield (93 mg, 0.35 mmol).  
Rf  = 0.56 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.26 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 3.70 (d, J = 13.1 Hz, 1H), 
3.65 (d, J = 13.1 Hz, 1H), 3.52 (dddd, J = 19.9, 10.7, 6.1, 3.0 Hz, 4H), 3.34 (s, 3H), 2.58 (dqd, J = 8.7, 
6.6, 4.8 Hz, 1H), 2.45 (dd, J = 11.6, 8.4 Hz, 1H), 2.36 (dd, J = 11.6, 4.9 Hz, 1H), 2.28 – 2.16 (m, 3H), 
2.10 (ddd, J = 11.2, 6.1, 3.1 Hz, 2H), 0.73 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 159.25, 133.54, 129.55, 114.09, 67.56, 59.02, 54.83, 53.68, 51.68, 48.90, 
11.82 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O2, 265.1916; found, 265.1913.  
 
N-(4-methoxybenzyl)-2-(piperidin-1-yl)propan-1-amine, 149b: The 
general secondary allyl amine hydroamination procedure A was followed 
using allyl amine 170 (89 mg, 0.50 mmol, 1.00 equiv.) and piperidine (247 
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μL, 2.5 mmol, 5.0 equiv., freshly distilled). Diamine 149b was isolated as a pale yellow oil in 55% yield 
(72 mg, 0.28 mmol). 
Rf  = 0.60 (1:9 NH4OH/CHCl3).   
1H NMR (C6D6, 500 MHz) δ 7.32 (d, J = 8.2 Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 3.76 (d, J = 13.1 Hz, 1H), 
3.72 (d, J = 13.1 Hz, 1H), 3.33 (s, 3H), 2.82 – 2.72 (m, 1H), 2.60 – 2.53 (m, 1H), 2.43 (ddd, J = 11.5, 4.9, 
1.0 Hz, 1H), 2.38 (ddd, J = 10.9, 7.2, 3.4 Hz, 2H), 2.24 – 2.12 (m, 2H), 1.77 (brs, 1H), 1.53 – 1.36 (m, 
4H), 1.30 (p, J = 6.0 Hz, 2H), 0.78 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz) δ 159.17, 133.84, 129.53, 114.05, 59.37, 54.82, 53.80, 52.30, 49.44, 27.08, 
25.46, 11.42 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C16H27N2O, 263.2123; found, 263.2119.  
 
N-(4-methoxybenzyl)-2-(4-ethylpiperazin-1-yl)propan-1-amine, 171: 
The general secondary allyl amine hydroamination procedure B was 
followed using allyl amine 170 (89 mg, 0.50 mmol, 1.00 equiv.) and 1-
ethylpiperazine (318 μL, 2.5 mmol, 5.0 equiv., freshly distilled). Diamine 
171 was isolated as yellow oil in 77% yield (112 mg, 0.39 mmol). 
Rf  = 0.28 (1:8 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ 7.32 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 3.77 (d, J = 13.1 Hz, 1H), 
3.72 (d, J = 13.2 Hz, 1H), 3.33 (s, 3H), 2.78 (dqd, J = 8.9, 6.6, 4.8 Hz, 1H), 2.60 – 2.41 (m, 5H), 2.41 – 
2.28 (m, 6H), 2.24 (qd, J = 7.2, 0.9 Hz, 2H), 0.99 (t, J = 7.2 Hz, 3H), 0.80 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 159.26, 133.41, 129.65, 114.08, 58.55, 54.81, 53.82, 53.64, 52.61, 51.96, 
12.68, 11.80 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C17H30N3O, 292.2389; found, 292.2384. 
 
N-(4-methoxybenzyl)-2-(pyrrolidin-1-yl)propan-1-amine, 149e: The 
general secondary allyl amine hydroamination procedure A was followed 
using allyl amine 170 (89 mg, 0.50 mmol, 1.00 equiv.) and pyrrolidine (208 
μL, 2.5 mmol, 5.0 equiv., freshly distilled). Diamine 149e was isolated as a 
pale yellow oil in 80% yield (99 mg, 0.4 mmol). 
Rf  = 0.62 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ  7.30 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 3.72 (s, 2H), 3.32 (s, 3H), 
2.66-2.51 (m, 3H), 2.43-2.36 (m, 4H), 2.18 (br s, 1H), 1.59-1.53 (m, 4H), 1.08 (d, J = 6.4 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz) δ 159.22, 133.58, 129.59, 114.05, 57.82, 54.79, 54.02, 53.99, 50.27, 23.93, 
15.61 ppm. 
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HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O, 249.1967; found, 249.1967. 
 
N-(4-bromobenzyl)-2-morpholinopropan-1-amine, 154:  The general 
secondary allyl amine hydroamination procedure A was followed using 
substrate (41 mg, 0.2 mmol, 1.00 equiv.) and morpholine (121 μL, 1.4 mmol, 
7.0 equiv., freshly distilled). Diamine 154 was isolated as a pale yellow oil in 
58% yield (33 mg, 0.11 mmol).  
Rf  = 0.40 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz): δ 7.31 (d, J = 8.3 Hz, 2H), 6.99 (d, J = 8.3 Hz, 2H), 3.55 (ddd, J = 9.3, 6.2, 
2.9 Hz, 2H), 3.50 (ddd, J = 10.8, 6.2, 2.9 Hz, 2H), 3.46 (s, 2H), 2.51 (dqd, J = 8.6, 6.6, 4.7 Hz, 1H), 2.32 
(dd, J = 11.6, 8.5 Hz, 1H), 2.26 – 2.18 (m, 3H), 2.08 (ddd, J = 11.1, 6.2, 3.0 Hz, 2H), 1.55 (s, 1H), 0.71 
(d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 140.65, 131.65, 130.02, 120.83, 67.54, 59.05, 53.38, 51.76, 48.88, 11.79 
ppm. 
 
2-morpholino-N-(thiophen-2-ylmethyl)propan-1-amine, 172:  The general 
secondary allyl amine hydroamination procedure A was followed using substrate 
(46 mg, 0.30 mmol, 1.00 equiv.) and morpholine (180 μL, 2.1 mmol, 7.0 equiv., 
freshly distilled). Diamine 172 was isolated as a pale yellow oil in 76% yield (55 
mg, 0.23 mmol).  
Rf  = 0.37 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz) 1H NMR (500 MHz, Benzene-d6) δ 6.90 (dd, J = 5.0, 1.2 Hz, 1H), 6.82 – 6.79 
(m, 1H), 6.77 (dd, J = 5.0, 3.4 Hz, 1H), 3.81 (dd, J = 2.9, 0.8 Hz, 2H), 3.53 (dddd, J = 20.3, 10.9, 7.0, 3.1 
Hz, 4H), 2.52 (dqd, J = 8.5, 6.6, 4.9 Hz, 1H), 2.43 (dd, J = 11.5, 8.5 Hz, 1H), 2.34 (dd, J = 11.6, 4.8 Hz, 
1H), 2.22 (ddd, J = 9.4, 5.9, 2.9 Hz, 2H), 2.07 (ddd, J = 10.4, 5.8, 3.1 Hz, 2H), 0.70 (d, J = 6.6 Hz, 3H) 
ppm. 
13C NMR (C6D6, 125 MHz): δ 146.00, 128.34, 126.70, 124.53, 67.55, 58.97, 51.60, 48.90, 48.84, 11.74 
ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C12H21N2OS 241.1375; found 241.1372. 
 
3,7-dimethyl-N-(2-morpholinopropyl)octa-2,6-dien-1-amine, 173:  
The general secondary allyl amine hydroamination procedure A was 
followed using substrate (76 mg, 0.40 mmol, 1.00 equiv.) and 
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morpholine (242 μL, 2.8 mmol, 7.0 equiv., freshly distilled). Diamine 173 was isolated as a pale yellow 
oil in 48% yield (52 mg, 0.19 mmol) as a mixture of diastereomers.  
Rf  = 0.24 (1:9 NH4OH/CHCl3). 
1H NMR (C6D6, 500 MHz) 1H NMR (500 MHz, Benzene-d6) δ 5.48 (t, J = 6.6 Hz, 1H), 5.26 – 5.17 (m, 
1H), 3.57 (ddtd, J = 14.1, 10.8, 8.0, 7.1, 3.1 Hz, 4H), 3.31 – 3.24 (m, 2H), 2.60 (dq, J = 12.8, 6.5 Hz, 1H), 
2.54 (ddd, J = 11.5, 8.3, 5.2 Hz, 1H), 2.42 (dt, J = 11.5, 4.4 Hz, 1H), 2.32 (ddd, J = 9.3, 5.9, 2.8 Hz, 2H), 
2.20 – 2.12 (m, 5H), 2.09 – 2.04 (m, 1H), 1.70 – 1.61 (m, 7H), 1.55 (d, J = 10.1 Hz, 3H), 0.80 (d, J = 6.5 
Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): 13C NMR (126 MHz, Benzene) δ 137.09, 136.87, 131.57, 131.32, 125.65, 
124.76, 124.74, 67.61, 59.19, 52.50, 52.36, 49.09, 47.77, 47.67, 40.10, 32.55, 27.26, 27.03, 25.89, 23.61, 
17.78, 16.37, 12.04 ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C17H33N2O 281.2593; found 281.2594. 
 
N-(2-morpholinopropyl)cyclohexanamine, 159:  The general secondary allyl 
amine hydroamination procedure A was followed using dppp instead of dppb and 
using substrate (89 mg, 0.50 mmol, 1.00 equiv.) and morpholine (219 μL, 2.5 mmol, 
5.0 equiv., freshly distilled). Diamine 159 was isolated as a pale yellow oil in 70% 
yield (93 mg, 0.35 mmol).  
1H NMR (C6D6, 500 MHz) 1H NMR (499 MHz, Benzene-d6) δ 3.58 (dtq, J = 17.0, 6.2, 3.1 Hz, 4H), 2.58 
(dq, J = 13.2, 6.5 Hz, 1H), 2.51 – 2.42 (m, 2H), 2.34 (dtd, J = 19.6, 7.8, 5.9, 3.3 Hz, 3H), 2.16 (ddd, J = 
10.4, 6.0, 3.0 Hz, 2H), 1.88 (d, J = 11.9 Hz, 1H), 1.81 (d, J = 12.2 Hz, 1H), 1.70 (ddd, J = 16.9, 8.6, 5.0 
Hz, 2H), 1.58 – 1.51 (m, 1H), 1.29 – 1.11 (m, 6H), 0.80 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 67.65, 59.28, 57.28, 49.96, 48.92, 34.14, 26.75, 25.34, 25.25, 11.96 ppm. 
 
3.4. Experimental Procedures of Chapters 2.2.5 and 2.2.6 
General Primary Allyl Amine Hydroamination Procedure A: 
 
[(DPEphos)Rh(COD)]BF4 (8.4 mg, 0.01 mmol, 2.0 mol %), allylamine substrate (0.50 mmol, 1.0 
equiv.), amine nucleophile (3.0 mmol, 3.0 equiv.), and dry CH3CN (223 μL) were added to an oven-dried 
4 mL vial equipped with a stir bar in the glove box. The resulting solution was allowed to stir for 2 h at 60 
°C.  The reaction vial was cooled to room temperature and was concentrated in vacuo followed by drying 
under high vacuum (0.05 mm Hg) for 1 h to afford the crude diamine as yellow oil. The diamine was further 
dissolved in CHCl3 (10 mL). 6 M HCl was then added to the flask until a pH ~1 was obtained. The organic 
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layer was then discarded and the aqueous layer was washed with CHCl3 (20 mL  3).  The final aqueous 
layer was basified with 3 M NaOH until a pH ~12 was obtained.  The aqueous layer was extracted with 
CHCl3 (30 mL  3).  The organic extracts were combined, dried over anhydrous MgSO4, and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to afford 
pure diamine. 
General Primary Allyl Amine Hydroamination Procedure B: 
 
[(DPEphos)Rh(COD)]BF4 (25 mg, 0.030 mmol, 7.5 mol %), allylamine substrate (54 mg, 0.40 mmol, 
1.0 equiv.), and dry CH3CN (100 μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the 
glove box. To the reaction mixture was added primary amine nucleophile (2.0 mmol, 5.0 equiv.). The 
resulting solution was allowed to stir for 24 h at 60 °C.  After 24 h, the reaction vial was cooled to room 
temperature. Purification of the crude diamine by silica gel chromatography (10 g silica, 100% CHCl3 to 
3% NH4OH : 1% MeOH: 96% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing 
aqueous layer, and adding methanol) afforded the pure diamine after drying under high vacuum (0.05 mm 
Hg) at 60 °C for 1 h. 
 
2-morpholinopropan-1-amine, 177a: [(DPEphos)Rh(COD)]BF4 (14.2 mg, 0.017 
mmol, 2.0 mol %), allylamine (64 μL, 0.85 mmol, 1.00 equiv.) and dry CH3CN (223 
μL) were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To 
the reaction mixture was added morpholine (446 μL, 5.1 mmol, 6.0 equiv.). The resulting solution was 
allowed to stir for 24 h at 60 °C. After 24 h, the reaction vial was cooled to room temperature and 
concentrated in vacuo followed by drying under high vacuum (15 mm Hg) for 10 min to afford crude 8a as 
a yellow oil. Purification of the crude diamine by silica gel chromatography (3 X 9 cm2,  NH4OH : CHCl3 
(1:20 then 1:15 then 1:6 followed by 1:3) v/v prepared by extracting saturated NH4OH with CHCl3, 
removing aqueous layer, and adding methanol; the column was set up using 1:20 NH4OH : CHCl3 as eluent) 
afforded pure diamine 177a as a pale yellow oil in  20% yield (25 mg, 0.17 mmol) after drying under high 
vacuum (15 mm Hg) for 10 min. A second column of the remained residue (came down the column as 
mixture of diamine, morpholine and some unknown impurities from the first column) with same conditions 
gave another batch of diamine 177a in 25% yield (31 mg, 0.21 mmol).  The remaining mixture contained 
diamine 177a and morpholine which was kept under high vacuum (15 mm Hg) for 10 min to afford the 
third batch of diamine 177a in 27% yield (33 mg, 0.23 mmol).  A total of 72% yield (89 mg, 0.61 mmol) 
of diamine 177a was obtained. The time slot for keeping the diamine 177a under the vacuum at 15 mm Hg 
is very crucial so that no product is lost to high vacuum.  The same reaction is done with 1 mol% of catalyst 
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resulted in no significant difference in yield. Also, an acid-base extraction prior to column does not alter 
the yield.  
Rf  = 0.34 (1:2 NH4OH/CHCl3). 
1H NMR (CDCl3, 500 MHz): δ 3.73 – 3.59 (m, 4H), 2.67 – 2.59 (m, 1H), 2.59 – 2.42 (m, 4H), 2.42 – 2.34 
(m, 2H), 1.52 (s, 2H), 0.91 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 67.39, 61.62, 48.61, 44.22, 11.40 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C7H17N2O, 145.1341; found, 145.1337.  
 
2-(piperidin-1)propan-1-amine, 177b: [(DPEphos)Rh(COD)]BF4 (14.2 mg, 0.017 
mmol, 2.0 mol %), allylamine (64 μL, 0.85 mmol, 1.00 equiv.) and dry CH3CN (223 μL) 
were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added piperidine (504 μL, 5.1 mmol, 6.0 equiv.). The resulting solution was allowed 
to stir for 24 h at 60 °C. After 24 h, the reaction vial was cooled to room temperature and concentrated in 
vacuo followed by drying under high vacuum (25 mm Hg) for 10 min to afford crude 177b as a yellow oil. 
Purification of the crude diamine by silica gel chromatography (3 X 9 cm2,  NH4OH : CHCl3 (1:20 then 
1:15 then 1:6 followed by 1:3) v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous 
layer, and adding methanol; the column was set up using 1:20 NH4OH : CHCl3 as eluent) afforded pure 
diamine 177b as a pale yellow oil in  23% yield (28 mg, 0.20 mmol) after drying under high vacuum (15 
mm Hg) for 10 min. A second column of the remained residue (came down the column as mixture of 
diamine, piperidine and some unknown impurities from the first column) with same conditions gave another 
batch of diamine 177b in 22% yield (27 mg, 0.19 mmol).  The remaining mixture contained diamine 177b 
and piperidine which was kept under high vacuum (25 mm Hg) for 10 min to afford the third batch of 
diamine 177b in 15% yield (18 mg, 0.13 mmol).  A total of 60% yield (73 mg, 0.52 mmol) of diamine 177b 
was obtained. The time slot for keeping the diamine 177b under the vacuum at 25 mm Hg is very crucial 
so that no product is lost to high vacuum.  The same reaction is done with 1 mol% of catalyst resulted in no 
significant difference in yield. Also, an acid-base extraction prior to column does not alter the yield. 
Rf  = 0.31 (1:2 NH4OH/CHCl3). 
1H NMR (CDCl3, 500 MHz): δ 2.65 (dd, J = 11.8, 8.1 Hz, 1H), 2.57 – 2.43 (m, 4H), 2.31 (ddd, J = 11.2, 
7.2, 3.5 Hz, 2H), 1.66 – 1.45 (m, 6H), 1.41 (q, J = 5.9 Hz, 2H), 0.88 (d, J = 6.3 Hz, 3H) ppm.  
13C NMR (CDCl3, 125 MHz): δ 62.02, 49.30, 44.69, 26.60, 24.98, 11.12 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C8H19N2, 143.1548; found, 143.1546.  
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2-(pyrrolidin-1-yl)propan-1-amine, 177c: [(DPEphos)Rh(COD)]BF4 (14.2 mg, 0.017 
mmol, 2.0 mol %), allylamine (64 μL, 0.85 mmol, 1.00 equiv.) and dry CH3CN (223 μL) 
were added to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the 
reaction mixture was added pyrrolidine (284μL, 3.4 mmol, 4.0 equiv.). The resulting solution was allowed 
to stir for 24 h at 60 °C. After 24 h, the reaction vial was cooled to room temperature and concentrated in 
vacuo followed by drying under high vacuum (15 mm Hg) for 10 min to afford crude 8e as a yellow oil. 
Purification of the crude diamine by silica gel chromatography (3 X 9 cm2,  NH4OH : CHCl3 (1:10 followed 
by 1:8) v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and adding 
methanol; the column was set up using 1:10 NH4OH : CHCl3 as eluent) afforded pure diamine 177c as a 
pale yellow oil in  37% yield (40 mg, 0.31 mmol) after drying under high vacuum (15 mm Hg) for 10 min. 
The remaining mixture contained diamine 177c and pyrrolidine which was kept under high vacuum (15 
mm Hg) for 10 min to afford the second batch of diamine 177c in 8% yield (9 mg, 0.07 mmol).  A total of 
45% yield (49 mg, 0.38 mmol) of diamine 177c was obtained. The time slot for keeping the diamine 177c 
under the vacuum at 15 mm Hg is very crucial so that no product is lost to high vacuum.  The same reaction 
is done with 1 mol% of catalyst resulted in no significant difference in yield. Also, an acid-base extraction 
prior to column does not alter the yield. 
Rf  = 0.22 (1:2 NH4OH/CHCl3). 
1H NMR (CDCl3, 500 MHz): δ 2.73 (d, J = 5.1 Hz, 2H), 2.56 (td, J = 5.4, 4.1, 2.6 Hz, 4H), 2.31 (dtd, J = 
11.5, 6.4, 5.0 Hz, 1H), 1.82 – 1.70 (m, 4H), 1.64 (s, 2H), 1.09 (d, J = 6.5 Hz, 3H) ppm.  
13C NMR (CDCl3, 125 MHz): δ 60.86, 51.01, 46.49, 23.40, 15.57 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C8H17N2, 129.1392; found, 129.1388.  
 
2-(4-methylpiperazin-1-yl)propan-1-amine, 177d: [(DPEphos)Rh(COD)]BF4 (14.2 
mg, 0.017 mmol, 2.0 mol %), allylamine (64 μL, 0.85 mmol, 1.00 equiv.) and dry 
CH3CN (223 μL) were added to an oven-dried 4 mL vial equipped with a stir bar in 
the glove box. To the reaction mixture was added N-methylpiperazine (377μL, 3.4 mmol, 4.0 equiv.). The 
resulting solution was allowed to stir for 24 h at 60 °C. After 24 h, the reaction vial was cooled to room 
temperature and concentrated in vacuo followed by drying under high vacuum (8 mm Hg) for 10 min to 
afford crude 177d as a yellow oil. Purification of the crude diamine by silica gel chromatography (3 X 9 
cm2,  NH4OH : CHCl3 (1:20 then 1:15 then 1:6 followed by 1:3) v/v prepared by extracting saturated 
NH4OH with CHCl3, removing aqueous layer, and adding methanol; the column was set up using 1:20 
NH4OH : CHCl3 as eluent) afforded pure diamine 177d as a pale yellow oil in  35% yield (48 mg, 0.30 
mmol) after drying under high vacuum (8 mm Hg) for 10 min. A second column of the remained residue 
(came down the column as mixture of diamine, N-methylpiperazine and some unknown impurities from 
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the first column) with same conditions gave another batch of diamine 177d in 22% yield (29 mg, 0.19 
mmol).  The remaining mixture contained diamine 177d and N-methylpiperazine which was kept under 
high vacuum (8 mm Hg) for 10 min to afford the third batch of diamine 177d in 6% yield (8 mg, 0.05 
mmol).  A total of 63% yield (85 mg, 0.54 mmol) of diamine 177d was obtained. The time slot for keeping 
the diamine 177d under the vacuum at 8 mm Hg is very crucial so that no product is lost to high vacuum.  
The same reaction is done with 1 mol% of catalyst resulted in no significant difference in yield. Also, an 
acid-base extraction prior to column does not alter the yield. 
Rf  = 0.22 (1:2 NH4OH/CHCl3).  
1H NMR (CDCl3, 500 MHz): δ 2.71 – 2.48 (m, 5H), 2.51 – 2.30 (m, 6H), 2.26 (s, 5H), 0.92 (d, J = 6.3 
Hz, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 60.91, 55.57, 55.46, 46.04, 44.23, 29.66, 11.38 ppm.   
HRMS (ESI-TOF) m/z: [M+H+] calculated for C8H20N3, 158.1657; found, 158.1650.  
 
Amines for the synthesis of 163b, 166, 168, and 164 were made using reported procedure.319 The syntheses 
of allylamines for the preparation of 1,2-diamines 178, 179, 180, and 181 are given below: 
 
1-(o-tolyl)prop-2-en-1-ol: To a flame dried 500 mL roundbottom flask charged with stir bar was added o-
tolualdehyde (2.3 mL, 20 mmol, 1.00 equiv.) in dry THF (100 mL).  The flask was placed under nitrogen 
and cooled to 0 °C.  Vinylmagnesium bromide (40 mL, 40 mmol, 2.0 equiv., 1 M solution) was added drop-
wise to the flask. The round bottom was warmed to room temperature and stirred for 1 hour. The reaction 
contents were quenched with the addition of saturated NH4Cl (75 mL).  The organic layer was removed 
and the aqueous layer was extracted with Et2O (75 mL  3 mL).  The organic layers were then combined 
and washed with brine (75 mL  1), dried with MgSO4, filtered, and concentrated under reduced pressure.  
Purification by silica gel column chromatography (20% ethyl acetate: 80% hexanes) gave the product as a 
colorless oil in 83% yield (2.46 g, 16.6 mmol).  
1H NMR (CDCl3, 400 MHz) δ 7.46 (dd, J = 7.3, 1.7 Hz, 1H), 7.25 – 7.14 (m, 3H), 6.04 (ddd, J = 17.3, 
10.3, 5.7 Hz, 1H), 5.42 (dt, J = 5.7, 1.5 Hz, 1H), 5.32 (dt, J = 17.2, 1.5 Hz, 1H), 5.21 (dt, J = 10.3, 1.4 Hz, 
1H), 2.36 (s, 3H), 1.88 (s, 1H) ppm. 
1-(o-tolyl)prop-2-en-1-amine: To an oven dried 50 mL Schlenk flask charged with stir bar was added 
[Ir(cod)2Cl]2 (100 mg, 0.15 mmol, 1.5 mol %), PN ligand (122 mg, 0.3 mmol, 3.0 mol %) in a glove box.  
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The Schlenk flask was capped with a rubber septum, removed from glove box, and placed under nitrogen.  
Dry DMF (20 mL) was added via syringe through the septum.  The Schlenk flask contents were stirred for 
15 minutes.  The alcohol (1.48 g, 10 mmol, 1.00 equiv.) was then added via syringe through the septum.  
The septum was removed, sulfamic acid (971 mg, 10 mmol, 1.00 equiv.) was added under positive flow of 
nitrogen, and the septum was replaced on the flask.  The contents were stirred 20 h at 50 °C.  DMF was 
removed under reduced pressure and the viscous residue was quenched with NaHCO3 (75 mL) and CH2Cl2 
(75 mL) was added. This was stirred for 30 minutes at 50 °C. The organic layer was removed and the 
aqueous layer extracted with CH2Cl2 (50 mL  3).  The organic layers were combined, dried with MgSO4, 
filtered, and concentrated under reduced pressure.  The reaction mixture was further dissolved in CHCl3 
(10 mL). To the reaction mixture was then added 6M HCl dropwise until a pH ~1 was obtained. The organic 
layer was separated. The aqueous layer was washed with CHCl3 (20 mL  3) and was then basified using 
NaOH (2 M) until a pH ~12 was obtained. The aqueous layer was extracted with CHCl3 (60 mL  3). All 
organic layers were then combined, dried over anhydrous MgSO4, filtered and concentrated in vacuo 
followed by drying under high vacuum (10 mm Hg) for 1 h to afford the amine as a yellow viscous oil in 
50% yield (736 mg, 5.0 mmol).  
1H NMR (CDCl3, 500 MHz) δ 7.39 (d, J = 7.2 Hz, 1H), 7.25 – 7.19 (m, 1H), 7.18 – 7.14 (m, 2H), 6.01 
(ddd, J = 17.2, 10.3, 5.8 Hz, 1H), 5.20 (dt, J = 17.2, 1.5 Hz, 1H), 5.13 (dt, J = 10.3, 1.4 Hz, 1H), 4.75 (dt, 
J = 5.8, 1.6 Hz, 1H), 2.38 (s, 3H), 1.80 (s, 2H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 142.08, 141.35, 135.19, 130.34, 126.76, 126.21, 125.53, 113.63, 54.03, 
19.09 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C10H14N, 148.1126; found, 148.1119.  
 
 
1-(4-(trifluoromethyl)phenyl)prop-2-en-1-amine:  To an oven dried 100 mL round bottom flask charged 
with stir bar was added 2-methylpropane-2-sulfinamide (2.42 g, 20 mmol), anhydrous CuSO4 (7.02 g, 44 
mmol, 2.2 equiv.) and dry CH2Cl2 (40 mL). To this suspension was added 4-(trifluoromethyl)benzaldehyde 
(3 mL, 22 mmol, 1.1 equiv.) and the resulting mixture was stirred at room temperature for 24 h. After 24 h, 
it was filtered through Celite, washed with CH2Cl2 (80 mL). The filtrate was concentrated in vacuo followed 
by drying under high vacuum (0.05 mm Hg) for 1 h to afford crude imine as a yellow solid. Purification of 
the crude imine by silica gel chromatography (75 mL silica, 70% CH2Cl2 : 30% Hexanes) afforded pure 
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imine as a white solid in 79% yield (4.38 g, 15.8 mmol). To an oven dried 100 mL round bottom flask 
charged with stir bar was added (E)-2-methyl-N-(4-(trifluoromethyl)benzylidene)propane-2-sulfinamide 
(2.77 g, 10 mmol) and dry THF (40 mL). The flask was then cooled to –78 °C using dry ice-acetone bath. 
To this cooled stirring solution, vinyl Grignard (30 mL, 30 mmol, 3 equiv., 1 M in THF) was added drop-
wise via syringe through the septum.  During addition, a precipitate was observed. The flask was stirred at 
–78 °C for 1 h and was gradually warmed to room temperature followed by stirring overnight. After 12 h, 
the flask was cooled to 0 °C and then the reaction was quenched by the drop-wise addition of saturated 
NH4Cl. The organic layer was separated and the aqueous layer was extracted with ether (50 mL  3). The 
organic extracts were combined, dried over anhydrous MgSO4, and filtered. The solution was concentrated 
in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h.  The resulting crude material was 
dissolved in MeOH (35 mL). To this solution was passed freshly generated dry HCl gas until the color of 
the solution turns black (~1.5 h). The resulting solution was stirred at room temperature for 12 h. The 
solution containing the amine salt was then concentrated in vacuo followed by addition of CHCl3 (20 mL). 
The crude amine salt was basified with 3 M NaOH until a pH ~12 was obtained.  The organic layer was 
separated and the aqueous layer was extracted with CHCl3 (50 mL  3).  The organic extracts were 
combined, dried over anhydrous MgSO4, and filtered. The solution was concentrated in vacuo followed by 
drying under high vacuum (0.05 mm Hg) for 1 h to afford pure amine as colorless oil in 70% yield (1.41g, 
7 mmol).  
1H NMR (C6D6, 500 MHz): δ 7.57 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 5.96 (ddd, J = 16.8, 10.2, 
6.3 Hz, 1H), 5.24 (dt, J = 17.1, 1.4 Hz, 1H), 5.12 (dt, J = 10.2, 1.3 Hz, 1H), 4.56 (d, J = 6.2 Hz, 1H), 1.55 
(s, 2H) ppm.   
13C NMR (C6D6, 125 MHz) δ 148.27, 141.45, 129.21 (q, 2JCF = 32.4 Hz), 126.93, 125.33 (q, 3JCF = 3.8 Hz), 
124.13 (d, 1JCF = 271.9 Hz), 114.38, 58.01 ppm. 
19F NMR (C6D6, 470 MHz) δ –62.81ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calcd for C10H11NF3, 202.0844; found, 202.0838.  
 
 
1-(4-chlorophenyl)prop-2-en-1-amine:  To an oven dried 100 mL round bottom flask charged with stir 
bar was added 2-methylpropane-2-sulfinamide (6.7 g, 55 mmol, 1.1 equiv.), anhydrous CuSO4 (17.6 g, 110 
mmol, 2.2 equiv.) and dry CH2Cl2 (80 mL). To this suspension was added 4-(chloro)benzaldehyde (7.0 g, 
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50 mmol, 1.0 equiv.) and the resulting mixture was stirred at room temperature for 24 h. After 24 h, it was 
filtered through Celite, washed with CH2Cl2 (80 mL). The filtrate was concentrated in vacuo followed by 
drying under high vacuum (0.05 mm Hg) for 1 h to afford crude imine as a yellow solid. Purification of the 
crude imine by silica gel chromatography (75 mL silica, 70% CH2Cl2 : 30% Hexanes) afforded pure imine 
as a white solid in 64% yield (7.8 g, 32 mmol). To an oven dried 100 mL round bottom flask charged with 
stir bar was added (E)-N-(4-chlorobenzylidene)-2-methylpropane-2-sulfinamide (7.8 g, 32 mmol) and dry 
THF (32 mL). The flask was then cooled to 0 °C. To this cooled stirring solution, vinyl Grignard (48 mL, 
48 mmol, 1.5 equiv., 1 M in THF) was added drop-wise via syringe through the septum.  During addition, 
a precipitate was observed. The flask was gradually warmed to room temperature followed by stirring 
overnight. After 12 h, the flask was cooled to 0 °C and then the reaction was quenched by the drop-wise 
addition of saturated NH4Cl. The organic layer was separated and the aqueous layer was extracted with 
ether (50 mL  3). The organic extracts were combined, dried over anhydrous MgSO4, and filtered. The 
solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h.  The 
resulting crude material was dissolved in MeOH (35 mL). To this solution was added 12M HCl (35 mL). 
The resulting solution was stirred at room temperature for 12 h. The solution was washed with CHCl3 (50 
mL  3). The aqueous layer was basified with 3 M NaOH until a pH ~12 was obtained.  The organic layer 
was separated and the aqueous layer was extracted with CHCl3 (50 mL  3).  The organic extracts were 
combined, dried over anhydrous MgSO4, and filtered. The solution was concentrated in vacuo followed by 
drying under high vacuum (0.05 mm Hg) for 1 h to afford pure amine 9f as colorless oil in 52% yield (2.76g, 
16.5 mmol).  
1H NMR (C6D6, 500 MHz): δ 1H NMR (500 MHz, Benzene-d6) δ 7.12 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 
8.6 Hz, 2H), 5.80 – 5.66 (m, 1H), 5.02 (d, J = 17.1 Hz, 1H), 4.89 (d, J = 10.2 Hz, 1H), 4.06 (d, J = 6.2 Hz, 
1H), 0.84 (s, 2H) ppm. 
13C NMR (C6D6, 125 MHz) δ. 13C NMR (126 MHz, Benzene) δ 143.64, 142.72, 132.86, 128.71, 128.54, 
113.49, 58.03 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C9H11NCl, 168.0580; found, 168.0578. 
 
 
undec-1-en-3-amine:  To an oven dried 100 mL round bottom flask charged with stir bar was added 2-
methylpropane-2-sulfinamide (2.42 g, 20 mmol), anhydrous CuSO4 (7.02 g, 44 mmol, 2.2 equiv.) and dry 
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CH2Cl2 (40 mL). To this suspension was added nonanal (3.8 mL, 22 mmol, 1.1 equiv.) and the resulting 
mixture was stirred at room temperature for 24 h. After 24 h, it was filtered through Celite, washed with 
CH2Cl2 (80 mL). The filtrate was concentrated in vacuo followed by drying under high vacuum (0.05 mm 
Hg) for 1 h to afford crude imine as a colorless oil. Purification of the crude imine by silica gel 
chromatography (75 mL silica, 70% CH2Cl2 : 30% Hexanes) afforded pure imine as a colorless oil in 87% 
yield (4.27 g, 17.4 mmol). To an oven dried 100 mL round bottom flask charged with stir bar was added 
(E)-2-methyl-N-nonylidenepropane-2-sulfinamide (1.96 g, 8 mmol) and dry THF (40 mL). The flask was 
then cooled to –78 °C using dry ice-acetone bath. To this cooled stirring solution, vinyl Grignard (30 mL, 
30 mmol, 3 equiv., 1 M in THF) was added drop-wise via syringe through the septum.  During addition, a 
precipitate was observed. The flask was stirred at –78 °C for 1 h and was gradually warmed to room 
temperature followed by stirring overnight. After 12 h, the flask was cooled to 0 °C and then the reaction 
was quenched by the drop-wise addition of saturated NH4Cl. The organic layer was separated and the 
aqueous layer was extracted with ether (50 mL  3). The organic extracts were combined, dried over 
anhydrous MgSO4, and filtered. The solution was concentrated in vacuo followed by drying under high 
vacuum (0.05 mm Hg) for 1 h.  The resulting crude material was dissolved in MeOH (35 mL). To this 
solution was passed freshly generated dry HCl gas until the color of the solution turns black (~1.5 h). The 
resulting solution was stirred at room temperature for 12 h. The solution containing the amine salt was then 
concentrated in vacuo followed by addition of CHCl3 (20 mL). The crude amine salt was basified with 3 M 
NaOH until a pH ~12 was obtained.  The organic layer was separated and the aqueous layer was extracted 
with CHCl3 (50 mL  3).  The organic extracts were combined, dried over anhydrous MgSO4, and filtered. 
The solution was concentrated in vacuo followed by drying under high vacuum (0.05 mm Hg) for 1 h to 
afford pure amine as colorless oil in 82% yield (1.11 g, 6.56 mmol). 
1H NMR (CDCl3, 400 MHz) δ 5.77 (ddd, J = 17.1, 10.2, 6.8 Hz, 1H), 5.09 (dt, J = 17.2, 1.6 Hz, 1H), 4.99 
(dd, J = 10.2, 1.5 Hz, 1H), 3.26 (q, J = 6.6 Hz, 1H), 1.46 – 1.06 (m, 16H), 0.87 (t, J = 6.8 Hz, 3H) ppm. 
13C NMR (CDCl3, 100 MHz): δ 143.67, 113.09, 54.52, 37.63, 31.87, 29.63, 29.55, 29.27, 26.07, 22.66, 
14.11 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C11H24N, 170.1909; found, 170.1909. 
 
2-morpholino-1-phenylpropan-1-amine, 163b: The general primary allyl amine 
hydroamination procedure A was followed using allyl amine substrate (67 mg, 0.50 
mmol, 1.00 equiv.) and morpholine (87 μL, 1.0 mmol, 2.0 equiv., freshly distilled). 
Diamine 163b was isolated as a pale yellow oil in 84% yield (93 mg, 0.42 mmol). 
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1H NMR (CDCl3, 500 MHz) δ 7.39 – 7.28 (m, 4H), 7.25 – 7.20 (m, 1H), 4.16 (d, J = 4.4 Hz, 1H), 3.66 
(ddd, J = 5.4, 3.7, 1.4 Hz, 4H), 2.63 (qd, J = 6.8, 4.4 Hz, 1H), 2.51 (tq, J = 11.3, 5.7, 4.7 Hz, 4H), 2.47 
(brs, 2H), 0.93 (d, J = 6.8 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz) δ 145.29, 128.25, 127.41, 126.79, 67.53, 65.89, 55.87, 51.19, 10.10 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H21N2O, 221.1654; found, 221.1645. 
 
2-morpholino-1-phenylpropan-1-amine, 163c: The general primary allyl amine 
hydroamination procedure A was followed using allyl amine substrate (55 mg, 0.40 
mmol, 1.00 equiv.) and N-methylpiperazine (120 μL, 1.2 mmol, 3.0 equiv., freshly 
distilled) and was run for 4 hours. Diamine 163c was isolated as a pale yellow oil in 
65% yield (59 mg, 0.25 mmol). 
1H NMR (CDCl3, 500 MHz) 1H NMR (500 MHz, Benzene-d6) δ 7.33 (d, J = 7.6 Hz, 2H), 7.22 (t, J = 7.6 
Hz, 2H), 7.12 (t, J = 7.2 Hz, 1H), 4.01 (d, J = 4.4 Hz, 1H), 2.50 – 2.38 (m, 5H), 2.24 (s, 4H), 2.11 (s, 3H), 
1.32 (s, 2H), 0.85 (d, J = 6.7 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz) δ 13C NMR (126 MHz, Benzene) δ 145.60, 128.19, 127.47, 126.69, 65.53, 
56.40, 56.14, 50.56, 46.31, 10.49 ppm. 
HRMS (EI-TOF) m/z: [M] calculated for C14H24N3 234.1970; found 234.1968. 
 
2-morpholino-1-phenylpropan-1-amine, 163d: The general primary allyl amine 
hydroamination procedure A was followed using allyl amine substrate (53 mg, 0.40 
mmol, 1.00 equiv.) and piperidine (37 μL, 0.44 mmol, 1.1 equiv., freshly distilled) and 
was run for 8 hours. Diamine 163d was isolated as a pale yellow oil in 57% yield (48 
mg, 0.22 mmol). 
1H NMR (C6D6, 500 MHz) δ 7.26 (d, J = 6.9 Hz, 2H), 7.13 – 6.97 (m, 3H), 3.87 (d, J = 4.2 Hz, 1H), 2.45 
– 2.37 (m, 1H), 2.33 – 2.18 (m, 4H), 1.28 (d, J = 57.9 Hz, 10H), 0.84 (d, J = 6.4 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz) δ 145.93, 127.95, 127.27, 126.44, 66.04, 57.19, 51.45, 26.88, 25.12, 10.23 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2, 219.1861; found, 219.1854. 
 
2-morpholino-1-(o-tolyl)propan-1-amine, 178:  The general primary allyl amine 
hydroamination procedure A was followed using allyl amine substrate (113 mg, 0.85 
mmol, 1.00 equiv.) and morpholine (223 μL, 1.2 mmol, 3.0 equiv., freshly distilled) and 
was run for 24 hours. Diamine 178 was isolated as a pale yellow oil in 75% yield (149 
mg, 0.64 mmol). 
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1H NMR (C6D6, 500MHz) δ 7.79 (d, J = 7.7 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 7.10 (td, J = 7.4, 1.4 Hz, 
1H), 7.04 (d, J = 7.5 Hz, 1H), 4.26 (d, J = 3.8 Hz, 1H), 3.54 (t, J = 4.6 Hz, 4H), 2.27 (dq, J = 12.2, 3.8, 
2.9 Hz, 5H), 2.14 (s, 3H), 1.08 (s, 2H), 0.85 (d, J = 6.7 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz): δ 142.94, 134.98, 130.51, 127.75, 126.67, 126.13, 67.60, 63.14, 51.79, 51.29, 
19.47, 10.06 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2O, 235.1810; found, 235.1806.  
 
1-(4-methoxyphenyl)-2-morpholinopropan-1-amine, 166: The general primary allyl 
amine hydroamination procedure A was followed using allyl amine substrate (82 mg, 
0.50 mmol, 1.00 equiv.) and morpholine (175 μL, 2.0 mmol, 4.0 equiv., freshly distilled) 
and was run for 24 hours. Diamine 166 was isolated as an off white solid in 80% yield 
(100 mg, 0.40 mmol). 
m.p. 63–65 °C. 
1H NMR (C6D6, 500 MHz) δ 7.27 (d, J = 8.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 3.95 (d, J = 4.1 Hz, 1H), 
3.55 (dd, J = 5.6, 3.8 Hz, 4H), 3.36 (s, 3H), 2.35 – 2.20 (m, 5H), 1.37 (s, 2H), 0.84 (d, J = 6.7 Hz, 3H) 
ppm. 
13C NMR (C6D6, 125 MHz) δ 159.04, 137.03, 128.37, 113.78, 67.58, 65.96, 55.34, 54.82, 51.29, 10.16 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C14H23N2O2, 251.1760; found, 251.1754. 
 
1-(4-bromophenyl)-2-morpholinopropan-1-amine, 168: The general primary allyl 
amine hydroamination procedure A was followed using allyl amine substrate (106 mg, 
0.50 mmol, 1.00 equiv.) and morpholine (87 μL, 1.0 mmol, 2.0 equiv., freshly distilled). 
Diamine 168 was isolated as an off white solid in 80% yield (120 mg, 0.40 mmol). 
m.p. 64–66 °C. 
1H NMR (C6D6, 500 MHz) δ 7.35 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 2H), 3.70 (d, J = 4.6 Hz, 1H), 
3.57 – 3.41 (m, 4H), 2.16 (dd, J = 6.0, 3.6 Hz, 4H), 2.09 (qd, J = 6.7, 4.6 Hz, 1H), 0.96 (s, 2H), 0.68 (d, J 
= 6.7 Hz, 3H) ppm. 
13C NMR (C6D6, 500 MHz) δ 144.33, 131.30, 129.19, 120.55, 67.46, 65.60, 55.34, 51.08, 9.97 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calcd for C13H20N2OBr, 299.0759; found, 299.0755. 
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1-(4-(trifluoromethyl)phenyl)-2-morpholinopropan-1-amine, 179: The general 
primary allyl amine hydroamination procedure A was followed using allyl amine 
substrate (64 mg, 0.32 mmol, 1.00 equiv.) and morpholine (56 μL, 0.64 mmol, 2.0 
equiv., freshly distilled). Diamine 179 was isolated as a clear oil in 91% yield (84 mg, 
0.29 mmol). 
1H NMR (C6D6, 500 MHz): δ 7.44 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 3.75 (d, J = 4.7 Hz, 1H), 
3.48 (t, J = 4.6 Hz, 4H), 2.21 – 2.08 (m, 5H), 1.10 – 0.92 (m, 2H), 0.66 (d, J = 6.7 Hz, 3H) ppm.   
13C NMR (C6D6, 125 MHz) δ 149.63, 128.95 (q, 2JCF = 32.1 Hz), 125.25 (d, 1JCF = 271.7 Hz), 125.07 (q, 
3JCF = 3.8 Hz), 67.42, 65.59, 55.65, 51.00, 9.91 ppm. 
19F NMR (C6D6, 470 MHz) δ –62.23 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calcd for C14H20N2OF3, 289.1528; found, 289.1524. 
 
1-(4-chlorophenyl)-2-morpholinopropan-1-amine, 180: The general primary allyl 
amine hydroamination procedure A was followed using allyl amine substrate (64 mg, 
0.38 mmol, 1.00 equiv.) and morpholine (70 μL, 0.8 mmol, 2.0 equiv., freshly distilled). 
Diamine 180 was isolated as a clear oil in 81% yield (78 mg, 0.31 mmol). 
1H NMR (500 MHz, Benzene-d6) δ 7.19 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 
3.74 (d, J = 4.6 Hz, 1H), 3.52 – 3.47 (m, 4H), 2.17 (dd, J = 5.4, 3.1 Hz, 4H), 2.15 – 
2.09 (m, 1H), 1.06 (s, 2H), 0.69 (d, J = 6.7 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 143.89, 132.37, 128.81, 128.33, 67.46, 65.67, 55.33, 51.07, 9.98 ppm.  
 
2-morpholinoundecan-3-amine, 181: The general primary allyl amine hydroamination 
procedure A was followed using allyl amine substrate (85 mg, 0.50 mmol, 1.00 equiv.) 
and morpholine (175 μL, 2.0 mmol, 4.0 equiv., freshly distilled) and was run for 24 
hours. (175 μL, 2.0 mmol, 4.0 equiv.). The resulting solution was allowed to stir for 24 
h at 60 °C.  Diamine 181 was isolated as a clear oil in 80% yield (103 mg, 0.40 mmol).  
1H NMR (C6D6, 500 MHz) δ 3.59 (ddd, J = 5.3, 3.9, 2.5 Hz, 4H), 2.68 (ddd, J = 8.2, 5.2, 3.0 Hz, 1H), 
2.27 (tq, J = 11.0, 6.3, 5.0 Hz, 4H), 1.96 (qd, J = 6.6, 5.2 Hz, 1H), 1.48 (dd, J = 7.5, 3.0 Hz, 2H), 1.40 – 
1.26 (m, 11H), 1.21 (dt, J = 10.0, 8.2 Hz, 1H), 0.97 – 0.88 (m, 3H), 0.83 (d, J = 6.6 Hz, 3H), 0.77(s, 2H) 
ppm. 
13C NMR (C6D6, 125 MHz): δ 67.62, 64.37, 52.18, 50.80, 35.42, 32.39, 30.45, 30.18, 29.87, 27.05, 23.17, 
14.42, 9.52 ppm.  
HRMS (ESI-TOF) m/z: [M+H+] calcd for C15H33N2O, 257.2593; found, 257.2595. 
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4-morpholino-1-phenylpentan-3-amine, 164: The general primary allyl amine 
hydroamination procedure A was followed using allyl amine substrate (81 mg, 0.50 
mmol, 1.00 equiv.) and morpholine (175 μL, 2.0 mmol, 4.0 equiv., freshly distilled) and 
was run for 24 hours. Diamine 164 was isolated as a clear oil in 75% yield (93 mg, 0.38 
mmol).   
1H NMR (C6D6, 500 MHz) δ 7.22 – 7.17 (m, 4H), 7.12 – 7.07 (m, 1H), 3.60 – 3.48 (m, 4H), 2.75 (ddd, J 
= 13.6, 9.8, 5.1 Hz, 1H), 2.60 – 2.51 (m, 2H), 2.16 (dtdd, J = 15.4, 11.2, 7.2, 3.5 Hz, 4H), 1.89 (dt, J = 
13.1, 6.5 Hz, 1H), 1.82 (dddd, J = 13.3, 10.2, 7.1, 3.3 Hz, 1H), 1.42 (dddd, J = 13.7, 9.5, 8.8, 5.1 Hz, 1H), 
0.75 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (C6D6, 125 MHz) δ 143.14, 128.83, 128.69, 126.08, 67.58, 64.51, 51.79, 50.52, 37.27, 33.14, 
9.40 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2O, 249.1967; found, 249.1969. 
 
Determining the Enantiospecificity of the Hydroamination reaction: 
Racemic 1-phenylprop-2-en-1-amine was synthesized according to the above procedure. 
Enantioenriched substrate was synthesized using the general procedure for the synthesis of primary amines 
with (S)-2-methylpropane-2-sulfinamide in a 1:3 enantiomeric ratio.326 
 
The enantiomeric ratio of the corresponding hydroamination product was determined by chiral HPLC 
of the BOC-protected products. Racemic and enantioenriched products were synthesized according to the 
general allylamine hydroamination procedure A. After isolation, 1,2-diamines 163b and 163b* were 
subjected to BOC-protection conditions. The 1,2-diamine substrate (49 mg, 0.224 mmol, 1.0 equiv.) was 
dissolved in DCM (225 µL, 1M). Boc2O (73 mg, 0.45 mmol, 1.5 equiv.) was added dropwise and stirred at 
room temperature for 2 hours. The enantiomeric ratio of both products was determined by chiral HPLC 
(IC-3 column, 3% IPA in hexanes (99:1 hexanes: Et2NH), λ = 254 nm, flow rate = 1.00 mL/min).   
1H NMR (CDCl3, 500 MHz) δ 7.30 (d, J = 7.3 Hz, 2H), 7.25 (d, J = 7.7 Hz, 3H), 5.46 (s, 1H), 4.78 (s, 
1H), 3.64 (s, 4H), 2.82 – 2.72 (m, 1H), 2.47 (s, 4H), 1.44 (s, 9H), 0.98 (d, J = 6.9 Hz, 3H) ppm. 
13C NMR (CDCl3, 126 MHz) δ 155.71, 141.07, 128.33, 127.17, 127.10, 79.74, 67.54, 63.89, 56.35, 50.92, 
28.65, 11.16 ppm. 
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N2,N2-dimethyl-1-phenylpropane-1,2-diamine, 182: [(DPEphos)Rh(COD)]BF4 (8.5 mg, 
0.010 mmol, 5.0 mol %) and amine substrate (27 mg, 0.20 mmol, 1.0 equiv.) were added 
to an oven-dried 4 mL vial equipped with a stir bar in the glove box. To the reaction mixture 
was added N,N-dimethylamine (1.0 mL, 1.4M in THF, 1.4 mmol, 7.0 equiv.). The resulting 
solution was allowed to stir for 24 h at 60 °C.  After 24 h, the reaction vial was cooled to room temperature. 
The reaction mixture was then concentrated in vacuo to afford the crude diamine 182 as yellow oil. 
Purification of the crude diamine by silica gel chromatography (10 g silica, 100% CHCl3 to 3% NH4OH : 
1% MeOH : 96% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, 
and adding methanol) afforded pure diamine 182 as a pale yellow oil in 80% yield (30 mg, 0.17 mmol). 
Rf  = 0.12 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.34 (d, J = 7.7 Hz, 2H), 7.21 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 4.00 
(d, J = 4.8 Hz, 1H), 2.34 – 2.26 (m, 1H), 2.07 (s, 6H), 1.47 (s, 2H), 0.86 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 145.55, 128.27, 127.45, 126.73, 66.32, 56.81, 42.90, 10.23 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C11H19N2, 179.1548; found, 179.1546. 
tr (min) Area (%) 
10.264 41.574 
11.687 58.426 
tr (min) Area (%) 
10.216 24.487 
11.544 75.513 
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(1R,2S)-N2-benzyl-N2-methyl-1-phenylpropane-1,2-diamine, 183: 
[(DPEphos)Rh(COD)]BF4 (8.5 mg, 0.010 mmol, 5.0 mol %), amine substrate (54 mg, 
0.40 mmol, 1.0 equiv.), and dry CH3CN (100 μL) were added to an oven-dried 4 mL 
vial equipped with a stir bar in the glove box. To the reaction mixture was added N-
methyl-N-benzylamine (242 mg, 2.0 mmol, 5.0 equiv.). The resulting solution was allowed to stir for 24 h 
at 60 °C.  After 24 h, the reaction vial was cooled to room temperature. The reaction mixture was then 
concentrated in vacuo to afford the crude diamine 183 as yellow oil. Purification of the crude diamine by 
silica gel chromatography (10 g silica, 100% CHCl3 to  3% NH4OH : 97% CHCl3 to 3% NH4OH : 3% 
MeOH: 97% CHCl3 v/v prepared by extracting saturated NH4OH with CHCl3, removing aqueous layer, and 
adding methanol) afforded pure diamine 183 as a pale yellow oil in 31% yield (32 mg, 0.13 mmol). 
Rf  = 0.35 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.22 (d, J = 6.8 Hz, 4H), 7.14 (d, J = 8.3 Hz, 8H), 7.11 – 7.04 (m, 4H), 3.77 
(d, J = 6.9 Hz, 1H), 3.41 (d, J = 13.6 Hz, 1H), 3.34 (d, J = 13.6 Hz, 1H), 2.67 (p, J = 6.7 Hz, 1H), 1.98 (s, 
3H), 0.97 (d, J = 6.6 Hz, 3H) ppm. 
13C NMR (126 MHz, CDCl3) δ 145.38, 140.15, 128.63, 128.19, 128.16, 127.16, 126.76, 126.74, 63.87, 
59.10, 58.72, 37.90, 10.02 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C17H23N2, 255.1861; found, 255.1862. 
 
N2-butyl-1-phenylpropane-1,2-diamine, 185: The general primary allyl amine 
hydroamination procedure B was followed using allyl amine substrate (54 mg, 0.40 
mmol, 1.0 equiv.) and N-butylamine (146 mg, 2.0 mmol, 5.0 equiv.). Diamine 185 was 
isolated as a pale yellow oil in 67% yield (57 mg, 0.28 mmol). 
Rf  = 0.20 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.34 (d, J = 7.6 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 3.93 
(d, J = 4.1 Hz, 1H), 2.79 – 2.72 (m, 1H), 2.51 (dt, J = 11.2, 7.0 Hz, 1H), 2.44 (dt, J = 11.2, 7.0 Hz, 1H), 
1.44 – 1.30 (m, 8H), 1.27 – 1.21 (m, 2H), 0.88 – 0.83 (m, 6H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.90, 128.31, 127.63, 126.91, 59.51, 58.57, 47.59, 33.09, 20.87, 15.34, 
14.30 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H23N2, 207.1861; found, 207.1871. 
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N2-isobutyl-1-phenylpropane-1,2-diamine, 186: The general primary allyl amine 
hydroamination procedure B was followed using allyl amine substrate (54 mg, 0.40 
mmol, 1.0 equiv.) and N-isobutylamine (146 mg, 2.0 mmol, 5.0 equiv.). Diamine 186 
was isolated as a pale yellow oil in 58% yield (49 mg, 0.24 mmol). 
Rf  = 0.20 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.34 (d, J = 7.3 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 3.86 
(d, J = 4.3 Hz, 1H), 2.73 – 2.67 (m, 1H), 2.34 (dd, J = 11.2, 6.5 Hz, 1H), 2.25 (dd, J = 11.2, 6.8 Hz, 1H), 
1.51 (dp, J = 13.3, 6.6 Hz, 1H), 1.10 (s, 3H), 0.88 – 0.82 (m, 9H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.89, 128.31, 127.61, 126.92, 59.55, 58.57, 55.98, 29.23, 20.91, 15.44 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C13H23N2, 207.1861; found, 207.1871. 
 
N2-isopropyl-1-phenylpropane-1,2-diamine, 187: The general primary allyl amine 
hydroamination procedure B was followed using allyl amine substrate (54 mg, 0.40 
mmol, 1.0 equiv.),  and N-isopropylamine (120 mg, 2.0 mmol, 5.0 equiv.). Diamine 187 
was isolated as a pale yellow oil in 60% yield (47 mg, 0.24 mmol). 
Rf  = 0.13 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.31 (d, J = 7.3 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 3.81 
(d, J = 4.0 Hz, 1H), 2.85 (qd, J = 6.4, 4.2 Hz, 1H), 2.71 (hept, J = 6.2 Hz, 1H), 0.98 (s, 3H), 0.92 (d, J = 6.2 
Hz, 3H), 0.89 (d, J = 6.2 Hz, 3H), 0.81 (d, J = 6.5 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.00, 128.37, 127.56, 127.03, 58.37, 55.93, 46.22, 23.21, 22.69, 14.84 
ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C12H21N2, 193.1705; found, 193.1710. 
 
N2-cyclohexyl-1-phenylpropane-1,2-diamine, 188: The general primary allyl amine 
hydroamination procedure B was followed using allyl amine substrate (54 mg, 0.40 
mmol, 1.0 equiv.) and N-cyclohexylamine (200 mg, 2.0 mmol, 5.0 equiv.). Diamine 
188 was isolated as a pale yellow oil in 66% yield (62 mg, 0.27 mmol). 
Rf  = 0.12 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.34 (d, J = 7.3 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 3.89 
(d, J = 4.0 Hz, 1H), 2.94 (qd, J = 6.4, 4.2 Hz, 1H), 2.43 (tt, J = 10.0, 3.7 Hz, 1H), 1.85 – 1.45 (m, 13H), 
1.20 – 1.04 (m, 5H), 1.02 – 0.90 (m, 4H), 0.85 (d, J = 6.5 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.84, 128.28, 127.65, 126.89, 59.08, 55.60, 53.94, 34.56, 34.23, 26.61, 
25.47, 25.33, 15.89 ppm. 
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HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H25N2, 233.2018; found, 233.2013. 
 
N2-(2-morpholinoethyl)-1-phenylpropane-1,2-diamine, 189: The general primary 
allyl amine hydroamination procedure B was followed using allyl amine substrate (54 
mg, 0.40 mmol, 1.0 equiv.) and 2-morpholinoethylamine (260 mg, 2.0 mmol, 5.0 
equiv.). Diamine 189 was isolated as a pale yellow oil in 58% yield (62 mg, 0.24 
mmol). 
Rf  = 0.28 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.33 (d, J = 7.2 Hz, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.09 (t, J = 7.3 Hz, 1H), 3.82 
(d, J = 5.0 Hz, 1H), 3.47 (q, J = 4.1 Hz, 4H), 2.73 – 2.65 (m, 1H), 2.57 – 2.50 (m, 1H), 2.44 (ddd, J = 11.7, 
6.8, 5.3 Hz, 1H), 2.28 – 2.14 (m, 3H), 2.07 (t, J = 4.4 Hz, 4H), 1.43 (s, 3H), 0.95 (d, J = 6.4 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.96, 128.39, 127.66, 127.04, 67.11, 59.96, 59.28, 58.60, 53.90, 44.33, 
15.75 ppm. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C15H26N3O, 264.2076; found, 264.2084. 
 
N2-(2-methoxyethyl)-1-phenylpropane-1,2-diamine, 190: The general primary allyl 
amine hydroamination procedure B was followed using allyl amine substrate (54 mg, 
0.40 mmol, 1.0 equiv.) and 2-methoxyethylamine (150 mg, 2.0 mmol, 5.0 equiv.). 
Diamine 190 was isolated as a pale yellow oil in 70% yield (59 mg, 0.28 mmol). 
Rf  = 0.13 (1:9 NH4OH /CHCl3). 
1H NMR (C6D6, 500 MHz) δ 7.33 (d, J = 7.2 Hz, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.09 (t, J = 7.3 Hz, 1H), 3.87 
(d, J = 4.1 Hz, 1H), 3.25 (t, J = 5.3 Hz, 2H), 3.06 (s, 3H), 2.77 – 2.66 (m, 2H), 2.61 (dt, J = 12.0, 5.2 Hz, 
1H), 1.27 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H) ppm. 
13C NMR (126 MHz, Benzene) δ 144.75, 128.28, 127.61, 126.87, 72.66, 59.39, 58.47, 58.45, 47.49, 14.95. 
HRMS (ESI-TOF) m/z: [M+H+] calculated for C12H21N2O, 209.1654; found, 209.1660. 
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